Current Clinical Trials Protocols and the Global Effort for Immunization against SARS-CoV-2

Gabriel N A Rego; Mariana P Nucci; Arielly H Alves; Fernando A Oliveira; Luciana C Marti; Leopoldo P Nucci; Javier B Mamani; Lionel F Gamarra

doi:10.3390/vaccines8030474

. 2020 Aug 25;8(3):474. doi: 10.3390/vaccines8030474

Current Clinical Trials Protocols and the Global Effort for Immunization against SARS-CoV-2

Gabriel N A Rego ^1,^†, Mariana P Nucci ^2,^†, Arielly H Alves ¹, Fernando A Oliveira ¹, Luciana C Marti ¹, Leopoldo P Nucci ³, Javier B Mamani ¹, Lionel F Gamarra ^1,^*

PMCID: PMC7564421 PMID: 32854391

Abstract

Coronavirus disease 2019 (COVID-19) is the biggest health challenge of the 21st century, affecting millions of people globally. The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has ignited an unprecedented effort from the scientific community in the development of new vaccines on different platforms due to the absence of a broad and effective treatment for COVID-19 or prevention strategy for SARS-CoV-2 dissemination. Based on 50 current studies selected from the main clinical trial databases, this systematic review summarizes the global race for vaccine development against COVID-19. For each study, the main intervention characteristics, the design used, and the local or global center partnerships created are highlighted. Most vaccine developments have taken place in Asia, using a viral vector method. Two purified inactivated SARS-CoV-2 vaccine candidates, an mRNA-based vaccine mRNA1273, and the chimpanzee adenoviral vaccine ChAdOx1 are currently in phase III clinical trials in the respective countries Brazil, the United Arab Emirates, the USA, and the United Kingdom. These vaccines are being developed based on a quickly formed network of collaboration.

Keywords: COVID-19, SARS-CoV-2, immunization, vaccine, research and development (R&D)

1. Introduction

In December 2019, in the Chinese city of Wuhan in China’s Hubei province an outbreak related to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)—that is, a virus genetically close to bat-CoV-RaTG13 and bat-SL-CoVZC45—emerged, leading to coronavirus disease 2019 (COVID-19). This infectious disease caused an unprecedented health emergency, which was declared a pandemic by the World Health Organization (WHO) on 11 March 2020 [1].

Subsequently, new approaches to vaccine development or the adoptive transfer of immunity were rapidly implemented in preclinical and clinical studies. These studies aimed to avoid infection and prevent the symptoms of COVID-19, a disease of heterogeneous symptoms caused by SARS-CoV-2. As of the end of June 2020, this virus had affected about 10 million people globally and killed about 560,000 individuals [2].

Currently, there is not yet a consolidated protocol or therapeutic strategy approved for COVID-19 critical patients [3]. At this moment, the best practices for the supportive management of respiratory acute hypoxemic failure must be used.

The initial treatment of COVID-19 was restricted to overall supportive care and critical care because no other appropriate therapies or vaccines existed. However, many clinical trials are investigating the effect of anti-inflammatories, antimalarials, antivirals, plasma therapy, cardiovascular drugs, antibiotics, cell therapy, and cancer drugs among other medications for COVID-19 treatment [4,5]. Dexamethasone and anticoagulant are suggested since some severe, critical, and deceased COVID-19 patients have significant coagulation dysfunction with increased D-dimer concentration, decreased platelet counts, and the prolongation of prothrombin time [6]. Regarding the prophylactic use of Bacilo Calmette–Guérin (BCG) (Pasteur Institute at Lille, France) vaccine against SARS-CoV-2, it was observed that previous BCG (Lille, France) immunization correlates with a lower incidence and gravity of the COVID-19 disease across different countries, even when the BCG (Lille, France) immunization was performed in childhood. Antimalarials such as chloroquine and hydroxychloroquine are being extensively investigated, but no strong evidence of their benefits has been released yet. Thus, there are no specific mechanisms or robust evidence of the efficacy of these therapeutic procedures [7].

Thus, during the pandemic caused by COVID-19, several vaccine candidates with attenuated virus, encoding, or presenting SARS-CoV-2 antigens have been developed globally, reaching clinical trial phases I or II for the evaluation of their safety and immunogenicity. These vaccines include those based on inactivated virus [8,9,10,11,12]; on nucleic acid platforms as messenger ribonucleic acid (mRNA) [13,14,15,16,17,18,19,20], self-amplifying RNA (saRNA) [21], and DNA/plasmids [22,23,24,25,26,27]; recombinant adenovirus serotypes platforms as adenoviral vector 5 [28,29,30,31,32], chimpanzee adenoviral vector ChAdOx1 [33,34], and combined serotypes vectors 5 and 26 [35,36]; recombinant viral protein subunits [37,38,39,40,41,42,43,44]; modified dendritic cells [45,46,47]; artificial antigen-presenting cells [48]; and virus-like particle (VLP) vaccine [49]. Six protocols are developing phase II and/or III clinical trials using the chimpanzee adenoviral vector ChAdOx1 [50,51,52], purified inactivated SARS-CoV-2 vaccine [53,54], and mRNA-1273 vaccine [55]. Several of these vaccines undergoing trials comprise new technology that has not been tested previously.

The advent of nanotechnology enables different mechanisms to target viruses—for instance, through the use of acid functionalized multi-walled carbon nanotubes comprising photo-activated molecules [56], or natural (such as chitosan) or synthetic (such as polyethyleneimine (PEI)) polymeric nanoparticles [57]. These kinds of nanomaterials are able to work as gene carriers and have the potential to deliver small interfering RNA (siRNA) in COVID-19 patients [57]. In addition, nanotechnology has enabled the development of new vaccines, including vaccines based on recombinant protein nanoparticles with or without Matrix M^TM adjuvant [42], and mRNA vaccines through the encapsulation of modified nucleoside mRNA inside lipidic nanocapsules [17,18,19,20,58], which confers plasticity in terms of antigen manipulation and a potentially rapid effect. Intense efforts are underway to expand the technological knowledge against COVID-19 as part of a global scientific effort to battle this virus. However, to date no review has been conducted about this global development effort and the associated cooperation networks used to test new vaccines. This lack of information empowers the movements of anti-vaccine groups [59].

Nanotechnological mRNA-1273 arises in clinical trials just two months following SARS-CoV-2 sequence identification and is currently one of the most advanced vaccines already in phase III clinical trial protocols (CTPs) [55]. Viral vector platforms enable protein overexpression, and their long-term stability can induce robust immune responses with a single dose. At present, the chimpanzee adenoviral vector from Oxford (ChAdOx1) is another advanced vaccine in study phase (II-III) [51,52] and phase III [50]. In addition, recombinant protein subunits, as immunologic adjuvants that use a squalene (TLR4) agonist [60], previously licensed to be delivered as vaccines for other conditions, can provide apparatus for the necessarily large-scale production of the newly developed vaccines [61].

The majority of the recently developed vaccines aim to stimulate antibody synthesis with the necessary potential to neutralize the SARS-CoV-2 spike protein (S protein) to prevent the uptake of the single-strand RNA of this virus in ACE2 receptor positive cells [62].The exceptions are the vaccines using an attenuated/inactivated whole virus, which would lead to broader immunization [10,11,63]. In addition, vaccines using antigen presenting cells and artificial antigen presenting cells (aAPC) will elicit a robust cellular immune response in addition to humoral immunity.

This review aims to highlight the global scientific effort in the fight against SARS-CoV-2 for the development of new immunization approaches through either conventional or novel vaccine strategies against SARS-CoV-2.

2. Methods

2.1. Search Strategy

This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Guideline [64]. We conducted a search for published protocols until 26 July 2020 in the subsequent clinical trial databases: ClinicalTrials.gov, the Chinese Clinical Trial Registry (ChiCTR), the European Union Clinical Trials Register, and the WHO COVID-19 global research database [65]. Next, we applied the keyword sequence (COVID-19 OR SARS-CoV-2) AND (vaccine OR immunization) in the search fields of these databases.

2.2. Inclusion and Exclusion Criteria

This review included only clinical trial protocols that addressed the development of vaccines for preventing infections caused by the SARS-CoV-2 virus.

The reasons for excluding studies were as follows: (i) clinical trial protocols for observational study; (ii) clinical trial protocols that were canceled or not approved until the date of searching in the analyzed databases; (iii) clinical trial protocols that used drugs for COVID-19 treatment not associated with a vaccine; (iv) clinical trial protocols that use existing vaccines for other diseases to prevent COVID-19—for example, BCG; and (v) clinical trials using plasma for therapeutic protocols.

2.3. Data Extraction, Data Collection, and Risk of Bias Assessment

In this systematic review, six authors (G.N.A.R., A.H.A., M.P.N., L.P.N., J.B.M., and F.A.O.) organized in pairs independently and randomly reviewed and evaluated the information recorded from the clinical trial protocols identified by the search strategy in the databases mentioned above. These same authors evaluated the protocols to decide whether the eligibility criteria were met. The discrepancies in the study selection and data extraction between the six authors were discussed with two other authors (L.C.M. and L.F.G.) and resolved.

G.N.A.R., M.P.N., F.A.O., L.P.N., A.H.A., and J.B.M. analyzed studies of active immunization for COVID-19 through vaccines. After the study selection, the authors G.N.A.R., L.C.M, and M.P.N. analyzed the description of the experimental vaccine; M.P.N., F.A.O., and J.B.M. analyzed the study design, research arms, and applied interventions; and A.H.A and L.P.N analyzed the collaborative network between companies and universities as well as the partnerships established between different centers and hospitals. The analysis of the clinical trials and the preparation of the tables were carried out by consensus. For each case of disagreement, two senior authors (L.C.M. and L.F.G.) decided on the addition or subtraction of data. The final inclusion of studies in this review was agreed with all the authors.

2.4. Data Analysis

All the results were described and presented using the percentage distribution for all the variables analyzed in the tables.

3. Results

3.1. Study Selection

After applying the search strategies in the databases, 200 clinical study protocols were identified (171 protocols in ClinicalTrials.gov, 13 in ChiCTR, 12 in the EU Clinical Trials Register, and 4 in the WHO COVID-19 global research database). The search strategy used the Preferred Items for Reporting Guideline for Systematic Reviews and Meta-Analyses (PRISMA) [64]. Based on the established inclusion and exclusion criteria, of 171 protocols identified in ClinicalTrials.gov, 135 clinical trials were excluded after screening (68 BCG vaccine protocols, 49 observational protocols, 1 suspended, and 17 that used convalescent plasma for passive immunization), leaving 36 protocols selected from these databases. Of the 13 protocols identified in ChiCTR, 5 were excluded after the analysis (3 were observational protocols, 1 was a canceled/not approved clinical trial protocol, and 1 protocol was described as an immune response induction method not specific for COVID-19/SARS-CoV-2), leaving 8 selected clinical trial protocols. Finally, of the 12 protocols registered in the EU Clinical Trials Register, 11 were excluded (7 BCG vaccine protocols, 2 using convalescent plasma, and 2 protocols that were also registered in ClinicalTrials.gov), leaving only 1 study selected from this database. In total, 50 clinical trial protocols for active immunization for COVID-19 through vaccine application [8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,66,67] were included in the present work.

3.2. Overview of Clinical Trial Protocols for Active Immunization for Covid-19

The selected clinical trials focused on interventional approaches for active immunization through the application of the various types of vaccines currently being developed against SARS-CoV-2 (Table 1).

Table 1.

Description of the trial vaccine.

ID Number	Phase	Vaccine Name	Properties	Vaccine Features	Coronavirus Target	Start Date	Completion Date	Progress (%)	Recruitment Status	Recruitment Country
ISRCTN89951424# [50]	III	ChAdOx1 nCoV-19	Non replicating viral vector	Chimpanzee r-ADV vaccine encoding S protein	S protein of SARS-CoV-2	05/01/2020	07/31/2021	18.9	Recruiting	Brazil
NCT04456595 [54]	III	Adsorbed inactivated SARS-CoV-2	Inactivated virus	Adsorbed SARS-CoV-2 (CN2 strain) vaccine inactivated by BPL	Multiple proteins of SARS-CoV-2	07/01/2020	10/01/2021	5.5	Not yet recruiting	Brazil
ChiCTR2000034780 [53]	III	Purified inactivated SARS-CoV-2	Inactivated virus	SARS-CoV-2 strain inactivated inside Vero Cells	Multiple proteins of SARS-CoV-2	07/16/2020	07/16/2021	2.7	Recruiting	United Arab Emirates
NCT04470427 [55]	III	mRNA1273	mRNA	LNP-encapsulated mRNA-1273 encoding S protein	S protein of SARS-CoV-2	07/27/2020	10/27/2022	0.0	Not yet recruiting	USA
NCT04400838 [51]	II-III	ChAdOx1 nCoV-19	Non replicating viral vector	Chimpanzee r-ADV vaccine encoding S protein	S protein of SARS-CoV-2	05/01/2020	08/01/2021	18.8	Not yet recruiting	United Kingdom
EudraCT2020-001228-32 ISRCTN90906759 [52]	II-III	ChAdOx1 nCoV-19	Non replicating viral vector	Chimpanzee r-ADV vaccine encoding S protein	S protein of SARS-CoV-2	03/02/2020	06/30/2021	30.1	Ongoing	United Kingdom
NCT04405076 [20]	II	mRNA1273	mRNA	LNP-encapsulated mRNA-1273 encoding S protein	S protein of SARS-CoV-2	05/29/2020	08/01/2021	13.5	Recruiting	USA
NCT04341389 [32]	II	Adenovirus Type 5 (Ad5-nCoV)	Non replicating viral vector	Serotype 5 r-ADV vaccine encoding S protein	Full-length S protein of SARS-CoV-2	04/12/2020	01/31/2021	35.7	Active, not recruiting	China
ChiCTR2000031781 [29]	II	Adenovirus Type 5 (Ad5-nCoV)	Non replicating viral vector	Serotype 5 r-ADV vaccine encoding S protein	Full-length S protein of SARS-CoV-2	04/12/2020	01/31/2021	35.7	Not yet recruiting	China
NCT04466085 [41]	II	CHO cells vaccine	Protein Subunit	Recombinant protein produced with CHO cells + adjuvant (RBD-Dimer)	S protein of SARS-CoV-2	07/12/2020	09/15/2021	3.3	Not yet recruiting	NR
NCT04445389 [25]	I-II	GX-19	DNA	DNA vaccine	Unspecified protein of SARS-CoV-2	06/17/2020	06/17/2022	5.3	Recruiting	Republic of Korea
NCT04444674 [33]	I-II	ChAdOx1 nCoV-19	Non replicating viral vector	Chimpanzee r-ADV vaccine encoding S protein	S protein of SARS-CoV-2	06/01/2020	12/01/2021	10.0	Not yet recruiting	South Africa
NCT04437875 [36]	I-II	Gam-COVID-Vac Lyo	Non replicating viral vector	Combined serotypes 5 and 26 r-ADV vectored vaccine encoding S protein	S protein of SARS-CoV-2	06/17/2020	08/15/2020	66.1	Recruiting	Russia
NCT04436471 [35]	I-II	Gam-COVID-Vac	Non replicating viral vector	Combined serotypes 5 and 26 r-ADV vectored vaccine encoding S protein	S protein of SARS-CoV-2	06/17/2020	08/15/2020	66.1	Recruiting	Russia
NCT04412538 [12]	I-II	Purified inactivated SARS-CoV-2	Inactivated virus	Purified inactivated SARS-CoV-2	Multiple proteins of SARS-CoV-2	05/15/2020	09/01/2021	15.2	Recruiting	China
NCT04398147 [30]	I-II	Adenovirus Type 5 (Ad5-nCoV)	Non replicating viral vector	Serotype 5 r-ADV vaccine encoding S protein intramuscularly	Full-length S protein of SARS-CoV-2	05/01/2020	08/01/2021	18.8	Not yet recruiting	Canada
NCT04386252 [46]	I-II	AV-COVID-19	Dendritic cells	Autologous DCs differentiated in vitro from monocytes incubated with IL-4 and GM-CSF loaded with antigens from SARS-CoV-2	Unspecified proteins of SARS-CoV-2	07/01/2020	03/01/2021	10.3	Not yet recruiting	USA
NCT04383574 [10]	I-II	Adsorbed inactivated SARS-CoV-2	Inactivated virus	Adsorbed SARS-CoV-2 (CN2 strain) vaccine inactivated by BPL	Multiple proteins of SARS-CoV-2	05/20/2020	07/20/2020	100	Completed	China
NCT04380701 [19]	I-II	BNT162	mRNA	LNP-encapsulated nucleoside modified mRNA (BNT162)	S protein of SARS-CoV-2	04/23/2020	08/01/2020	94.0	Recruiting	Germany
NCT04352608 [11]	I-II	Adsorbed inactivated SARS-CoV-2	Inactivated virus	Adsorbed SARS-CoV-2 (CN2 strain) vaccine inactivated by BPL	Multiple proteins of SARS-CoV-2	04/16/2020	12/13/2020	41.9	Recruiting	China
NCT04324606 EudraCT2020-001072-15 [34]	I-II	ChAdOx1 nCoV-19	Non replicating viral vector	Chimpanzee r-ADV vaccine encoding S protein	S protein of SARS-CoV-2	04/23/2020	05/01/2021	25.2	Active, not recruiting	United Kingdom
NCT04276896 [45]	I-II	Lentiviral Minigene vaccine (LV-SMENP)	Dendritic cells	DCs modified by lentiviral vector system (NHP/TYF) + CTLs	Multiple proteins of SARS-CoV-2	03/24/2020	12/31/2024	7.1	Recruiting	China
ChiCTR2000032459 [9]	I-II	Purified inactivated SARS-CoV-2	Inactivated virus	SARS-CoV-2 strain inactivated inside Vero Cells	Multiple proteins of SARS-CoV-2	04/28/2020	11/28/2021	15.4	Recruiting	China
ChiCTR2000031809 [8]	I-II	Purified inactivated SARS-CoV-2	Inactivated virus	SARS-CoV-2 strain inactivated inside Vero Cells	Multiple proteins of SARS-CoV-2	04/11/2020	11/10/2021	18.3	Not yet recruiting	China
ChiCTR2000030750 [47]	I-II	Dendritic cells vaccine	Dendritic cells	COVID-19 epitope gene recombinant chimeric DC vaccine	SARS-CoV-2 epitope	03/01/2020	02/28/2021	40.4	Not yet recruiting	China
EudraCT 2020-001038-36 [15]	I-II	BNT162	mRNA	LNP-encapsulated nucleoside modified mRNA (BNT162)	S protein epitope of SARS-CoV-2	04/20/2020	07/26/2020 *	NR	Ongoing	NR
NCT04447781 [24]	I-II	INO-4800	DNA	DNA plasmid (pGX9501) vaccine with electroporation (INO-4800)	Full-length S protein of SARS-CoV-2	06/22/2020	02/22/2022	5.6	Not yet recruiting	Republic of Korea
NCT04463472 [23]	I-II	AG0301-COVID19	DNA	DNA plasmid vaccine	Multiples antigens from SARS-CoV-2	06/29/2020	07/31/2021	6.8	Recruiting	Japan
CTRI/2020/07/026352 [22]	I-II	ZYCOV-D	DNA	DNA plasmid vaccine	S protein of SARS-CoV-2	07/13/2020	07/13/2021	3.6	Recruiting	India
CTRI/2020/07/026300/NCT04471519 [66]	I-II	Covaxin (BBV152)	Inactivated virus	Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152A, BBV152B and BBV152C)	Multiples antigens from SARS-CoV-2	07/13/2020	06/30/2021	3.7	Recruiting	India
NCT04470609 [67]	I-II	SARS-CoV-2 Vaccine	Inactivated virus	Purified inactivated SARS-CoV-2 vaccine	Multiples antigens from SARS-CoV-2	07/10/2020	11/10/2021	3.3	Enrolling by invitation	China
NCT04473690 [40]	I-II	KBP-COVID-19	Protein Subunit	RBD-based vaccine developed with fast-growing tobacco plant technology	RBD S protein of SARS-CoV2	07/25/2020	11/18/2021	0.2	Not yet recruiting	NR
ChiCTR2000034825 [14]	I-II	BNT162b1	mRNA	3 LNP-mRNAs	RBD S protein of SARS-CoV2	07/20/2020	12/31/2020	3.7	Recruiting	China
NCT04449276 EudraCT 2020-001286-36 [16]	I	CVnCoV	mRNA	mRNA vaccine	Unspecified protein of SARS-CoV-2	06/17/2020	08/31/2020	52.0	Recruiting	Germany
NCT04405908 [43]	I	SCB-2019	Protein subunit	Recombinant 2019-nCoV S protein subunit-trimer vaccine + AS03 or CpG 1018 + Alum adjuvants	S protein of SARS-CoV-2	06/19/2020	03/30/2021	13.0	Recruiting	Australia
NCT04334980 [26]	I	bacTRL-Spike	DNA	Genetically modified probiotic bacteria containing plasmid encoding S protein	S protein of SARS-CoV-2	04/30/2020	12/31/2021	14.3	Not yet recruiting	Canada
NCT04313127 [31]	I	Adenovirus Type 5 (Ad5-nCoV)	Non replicating viral vector	r-ADV vaccine encoding S protein	Full-length S protein of SARS-CoV-2	03/16/2020	12/20/2022	13.1	Active, not recruiting	China
NCT04299724 [48]	I	aAPC	aAPC lentiviral modified vector	aAPC modified by lentiviral vector system NHP/TYF	Multiple proteins of SARS-CoV-2	02/15/2020	12/31/2024	9.1	Recruiting	China
NCT04283461 [17]	I	mRNA-1273	mRNA	LNP-encapsulated mRNA-1273	S protein of SARS-CoV-2	03/16/2020	11/22/2021	21.4	Recruiting	USA
NCT04428073 [44]	I	Covax-19™	Protein subunit	Advax™ adjuvant with a recombinant SARS-CoV-2 S protein	S protein of SARS-CoV-2	07/01/2020	12/01/2021	4.8	Not yet recruiting	NR
ChiCTR2000034112 [13]	I	NR	mRNA	mRNA vaccine	RBD S protein of SARS-CoV2	06/25/2020	12/31/2021	5.6	Not yet recruiting	China
ChiCTR2000030906 [28]	I	Adenovirus Type 5 (Ad5-nCoV)	Non replicating viral vector	Serotype 5 r-ADV vaccine encoding S protein intramuscularly	Full-length S protein of SARS-CoV-2	03/16/2020	12/31/2020	45.5	Recruiting	China
NCT04445194 [39]	I	CHO cells vaccine	Protein Subunit	Adjuvanted recombinant protein (RBD-Dimer)	S protein of SARS-CoV-2	06/22/2020	09/20/2021	7.5	Recruiting	China
NCT04453852 [38]	I	Covax-19™	Protein Subunit	Advax™ adjuvant combined with a SARS-CoV-2 recombinantS protein	S protein of SARS-CoV-2	06/30/2020	07/01/2021	7.1	Recruiting	Australia
ACTRN12620000674932 [37]	I	SARS-CoV-2 Sclamp	Protein Subunit	Molecular clamp stabilized S protein with MF59 adjuvant	S protein of SARS-CoV-2	06/06/2020	07/26/2020 *	NR	Recruiting	Australia
ISRCTN17072692 [21]	I	LNP-nCoVsaRNA	saRNA	saRNA vaccine encoding S protein	S protein of SARS-CoV-2	04/01/2020	07/31/2021	23.9	Recruiting	United Kingdom
NCT04450004 [49]	I	Plant-derived VLP	VLP	Plant-derived VLP + CpG 1018 or AS03 adjuvants	S protein of SARS-CoV-2	07/10/2020	04/30/2021	5.4	Recruiting	Canada
NCT04368988 [42]	I	NVX-CoV2373	Protein subunit	Recombinant SARS CoV-2 S protein NP vaccine + Matrix M adjuvant	S protein of SARS-CoV-2	05/25/2020	07/31/2021	14.4	Recruiting	Australia
NCT04368728 [18]	I	BNT162	mRNA	LNP-encapsulated nucleoside modified mRNA (BNT162)	S protein epitope of SARS-CoV-2	04/29/2020	01/23/2023	8.8	Recruiting	USA
NCT04336410 [27]	I	INO-4800	DNA	DNA plasmid (pGX9501) vaccine with electroporation (INO-4800)	Full-length S protein of SARS-CoV-2	04/03/2020	07/01/2021	25.1	Recruiting	USA

Open in a new tab

Abbreviations: mRNA: messenger ribonucleic acid; Ad5-nCoV: recombinant adenovirus type 5; r-ADV: recombinant adenovirus-vectored; CHO: Hamster Ovary Cell; CTL: antigen-specific cytotoxic T cell; LV-SMENP: modifying Dendritic Cell with lentivirus vectors expressing COVID-19 minigene SMENP; DC: Dendritic Cell; KBP: Kentucky BioProcessing; SCB-2019: S-Trimer COVID-19 Vaccine; aAPC: artificial antigen presenting cells; NR: Not Reported; LNP: Lipid Nanoparticle; NP: nanoparticle; VLP: Virus Like Particle; INO-4800: INOVIO’s DNA vaccine candidate; DNA: deoxyribonucleic acid; S protein: Spike protein; CN2: strain CN2 for purified inactivated SARS-CoV-2 virus vaccine; RBD: receptor-binding domain; Ad26: recombinant adenovirus type 26; BPL: β-propiolactone GM-CSF: granulocyte-macrophage colony-stimulating factor; NHP/TYF: self-inactivating lentiviral vector system; AS03: squalene-based immunologic adjuvant; CpG 1018: cytosine phosphoguanine 1018—the adjuvant contained in HEPLISAV-B^®; Alum: potassium aluminum sulfate; MF59: immunologic adjuvant that uses squalene; saRNA: Self-amplifying ribonucleic acid; USA: United States of America. Note: # This clinical trial has a partnership with the study NCT04400838. * These clinical trials did not mention the study completion date, so we have not calculated the progression rate of these studies.

The distribution of these CTPs over the time by phase (Figure 1) shows that the phase I studies started in February. The number of new studies by month (Figure 1A) shows that the number of CTPs in phase I was triplicate and quadruplicate in March and April, respectively, as did the beginning of phase II and phase II-III concomitant studies. In May, the number of studies at phase I reduced to a single CTP, and the I-II phase studies declined by half compared to the previous month. In addition, a new study started phase III. In June, the total number of new CTPs was the same as presented in April, but half of the studies were phase I and the other half were phase I-II. In July, as well as in June, there were six new studies at phase I-II and a study in phase II, but the number of CTPs at phase I decreased by 33.3%. There is a clear oscillation in the number of CTPs at phase I over the months, less marked in CTP at phase I-II. At the same time, there occurred an increased number of new studies in phase III.

Over-time distribution of multiplatform vaccine clinical trials according to the study phase. (A) Clinical trial protocols beginning in each month classified by the phase of development. (B) Cumulative analysis of clinical trial phases over the months.

A cumulative analysis of the number of CTPs by phase (Figure 1B) shows a continuous increase in phase I-II CTPs, which also occurred in phase I studies with a slight oscillation between April and May. On the other hand, cumulatively, the number of phase II, II-III, and III studies has remained constant since March, with a slight increase in phase III CTPs between June and July.

3.3. Properties and Features of Vaccines against COVID-19

3.3.1. Nucleic Acid Vaccines

Regarding the CTPs targeting vaccine development and application, their platforms display a variety of characteristics and properties (Figure 2; Table 1). Nucleic acid vaccines are the ones most tested in CTPs at this moment (32%). They are based on a genetically engineered plasmid containing DNA (12% of the CTPs) or RNA (as mRNA and saRNA, comprising 20% of the CTPs) (Figure 2) usually encoding a selected antigen (mainly S protein).

Clinical trial protocols multiplatform distribution for the development of vaccine candidates based on nucleic acid platforms (blue colors) comprising RNA and DNA vaccines, non-replicating viral vectors (**red**), inactivated SARS-CoV-2 (**pink**), protein subunits (**light green**), virus-like particles (**dark green**), dendritic cells (**purple**), and artificial antigen presentation cells modified by lentiviral vector (**orange**). Abbreviations: VLP: Virus-like particle; aAPC: artificial antigen presentation cells; LMV: lentiviral modified vector.

RNA Vaccines

The mRNA was used in 18% of the selected clinical trials in different phases (I, I-II, II), including a phase III mRNA1273 vaccine CTP [55]. The mRNA1273 [17,20,55] and BioNTech 162 (BNT162) [14,15,18,19] vaccines used a lipid nanoparticle (LNP) encapsulated nucleoside modified mRNA encoding the S protein of SARS-CoV-2.

BNT162 by the BioNTech (BNT) and Pfizer companies embrace different RNA vaccine candidates, comprising two nucleoside modified mRNA (modRNA) vaccines, an uridine containing mRNA (uRNA) vaccine, and a saRNA vaccine. Besides this, two of them codify full-length S protein, and the others codify S protein receptor binding domain (RBD) [68]. Initially, studies with BNT were developed with the four mentioned BNT162 vaccines; however, more recently a CTP with China as the recruiting country applied only the BNT162b1 vaccine [14]. Other CTPs of the same vaccine are recruiting patients in Germany [19] and the USA [18]. BNT162 is being administered in a prime/boost regimen [14,15,18,19], in which the same immunogen is applied in the prime, and the booster CTP objective is to observe the immunogenicity of the subjects against S protein and RBD through IgG titration in healthy individuals [14,15,18,19].

The CTPs using mRNA1273 by Moderna TX Inc are all being completely developed in the USA [17,20,55]. This vaccine encodes full-length S protein. At phase I, this study tested different concentrations of mRNA at 10, 25, 50, 100, and 250 µg in different interventional arms [17]. In the phase III intervention, the established dose was 100 µg via intramuscular administration in two doses 28 days apart in healthy individuals over 18 years old [55].

The phase I German CureVac´s novel coronavirus (CVnCoV) CTP [16] and another mRNA vaccine CTP recruiting in China [13] encode an unspecific protein and an RBD S protein of SARS-CoV-2, respectively, but there is no information about the delivery systems. Recently, an vaccine based on self-amplifying RNA encapsulated by lipid nanoparticle (LNP-nCoVsaRNA) phase I used saRNA encoding S protein in the United Kingdom, which will produce more antigen per transfected cell due to the replicative element [21].

DNA Vaccines

DNA vaccines [22,23,24,25,26,27] were used in 12% of CTPs with different delivery systems. Plasmids encoding S protein (pGX9501) are delivered with CELLECTRA@2000 electroporation system in a phase I trial in the USA, with a 0.5 mg/dose and 1 mg/dose [27], and in a phase I-II trial in the Republic of Korea, with a 1 mg/dose and 2 mg/dose delivered in a population ranging from 18 to 64 years old in sequential assignment [24] in two doses, as shown in Table 2.

Table 2.

Study design, arms, and interventions.

ID Number	Rehearsal Center	Estimated Enrollment	Allocation	Intervention Model	Masking	Intervention (Route)	Arm	Dose (Day)	Age Range (Years)
ISRCTN89951424 [50]	Single center	2000	Randomized	Sequential Assignment	Single	ChAdOx1 nCoV-19 (i.m) or MenACWY (i.m)	2	ChAdOx1 nCoV-19: 5 × 10¹⁰ vp Men ACWY: 0.5 ml	18–55
NCT04456595 [54]	Multicenter	8870	Randomized	Parallel Assignment	Quadruple	Inactivated SARS-CoV-2 Vaccine (i.m. − deltoid muscle) × Placebo (i.m)	4	NR (2 times: 0,14)	>18
ChiCTR2000034780 [53]	Single center	15,000	Randomized	Parallel Assignment	Double	Inactivated SARS-CoV-2 Vaccine × Placebo	3	NR (2 times)	>18
NCT04470427 [55]	Multicenter	30,000	Randomized	Parallel Assignment	Quadruple	mRNA-1273 Vaccine (.i.m) × Placebo (i.m)	2	100 μg (2 times: 0,28)	>18
NCT04400838 [51]	Multicenter	10,260	Randomized	Sequential Assignment	Single	ChAdOx1 nCoV-19 (i.m) × MenACWY vaccine (licensed control vaccine (i.m)	14	2.5 × 10¹⁰ vp; 5 × 10¹⁰ vp (single or 2 times: 1,28)	>5
EudraCT2020-001228-32 ISRCTN90906759 [52]	Multicenter	10,260	Randomized	NR	Single	ChAdOx1 nCoV-19 (i.m) × MenACWY vaccine (licensed control vaccine (i.m)	5	NR	5–12; 18–55; >56
NCT04405076 [20]	Multicenter	600	Randomized	Sequential Assignment	Double	Crossover: mRNA-1273 SARS-COV-2 Vaccine <---> Placebo	4	50 mcg; 100 mcg (0)	18–54; >55
NCT04341389 [32]	Single center	508	Randomized	Crossover Assignment	Double	rAd5-nCoV (i.m) × Placebo (i.m)	3	1 × 10¹¹vp; 5 × 10¹⁰ vp (0)	>18
ChiCTR2000031781 [29]	Multicenter	500	Randomized	Parallel Assignment	Double	rAd5-nCoV (i.m) × Placebo (i.m)	3	5 × 10¹⁰vp; 1 × 10¹¹ vp	>18
NCT04466085 [41]	NR	900	Randomized	Parallel Assignment	Double	Recombinant new coronavirus vaccine (CHO cells) (i.m.− deltoid muscle) × Placebo (i.m − deltoid muscle)	6	25 μg/0.5 mL; 50 μg/0.5 mL (2 and 3 times: 0,1 month)	18–59
NCT04445389 [25]	Single center	190	Randomized	Parallel Assignment	Double	GX-19 (i.m) × Placebo (i.m)	3	GX-19 dose A; B (1, 29)	18–50
NCT04444674 [33]	Multicenter	2000	Randomized	Parallel assignment	Quadruple	ChAdOx1 nCoV-19 (i.m. − deltoid muscle x Placebo (i.m. − deltoid muscle)	8	5 × 10¹⁰ vp (single or 2 times; 0,28)	18–65
NCT04437875 [36]	Single center	38	Non-randomized	Parallel Assignment	None	rAd26 (i.m) × rAd5 (i.m.) × rAd26 + rAd5 (i.m.)	3	rAd26 (1), rAd5 (1), rAd26 (1) + rAd5 (21)	18–60
NCT04436471 [35]	Single center	38	Non-randomized	Parallel Assignment	None	rAd26 (i.m) × rAd5 (i.m.) × rAd26 + rAd5 (i.m.)	3	rAd26 (1), rAd5 (1), rAd26 (1) + rAd5 (21)	18–60
NCT04412538 [12]	Single center	942	Randomized	Parallel Assignment	Quadruple	Inactivated SARS-CoV-2 Vaccine × Placebo	8	50 U/0.5 mL; 100 U/0.5 mL; 150 U/0.5 mL (2 times: 0,14 or 0,28)	18–59
NCT04398147 [30]	Single center	696	Randomized	Parallel Assignment	Quadruple	rAd5-nCoV (i.m) × Placebo (i.m)	28	5 × 10¹⁰ vp; 10 × 10¹⁰ vp (single or 2 times: 0,56)	18–55;65–85;
NCT04386252 [46]	Single center	180	Randomized	Parallel Assignment	Quadruple	Dendritic cells vaccine × GM-CSF (s.c) × Placebo (s.c)	9	DC loaded with 1×, 10× and 30× antigen + 250 and 500 mcg GM-CSF (0)	>18
NCT04383574 [10]	Single center	422	Randomized	Parallel Assignment	Double	Inactivated SARS-CoV-2 vaccine × Placebo	4	300 SU/mL; 600 SU/mL; 1200 SU/mL (2 times: 0,28)	>60
NCT04380701 [19]	Single center	200	Non-randomized	Sequential Assignment	None	BNT162a1; BNT162b1; BNT162b2; BNT162c2	4	Escalating dose levels (BNT162a1, BNT162b1, BNT162b2); Single dose (BNT162c2)	18–55
NCT04352608 [11]	Single center	744	Randomized	Parallel Assignment	Quadruple	Inactivated SARS-CoV-2 vaccine (i.m) × Placebo (i.m.)	6	600 SU/0.5 mL; 1200 SU/0.5 mL (2 times: 0,14 or 0,28)	18–59
NCT04324606 EudraCT2020-001072-15 [34]	Multicenter	1090	Randomized	Sequential Assignment	Single	ChAdOx1 nCoV-19 (i.m) × MenACWY vaccine (i.m) ± Paracetamol (oral)	9	5 × 10¹⁰ vp (Single: 0)	18–55
NCT04276896 [45]	Multicenter	100	NR	Single Group Assignment	None	LV-SMENP-DC vaccine (s.c) and antigen-specific CTLs (i.v)	1	5 × 10⁶ DC + 1 × 10⁸ CTLs	0.5–80
ChiCTR2000032459 [9]	Single center	2128 (I: 480; II: 1648)	Randomized	Parallel Assignment	Double	Inactivated SARS-CoV-2 vaccine × Placebo	30 (Phase I); 38 (Phase II)	Low; Medium; High	>3
ChiCTR2000031809 [8]	Multicenter	1456 (I: 288; II: 1168)	Randomized	Parallel Assignment	Double	Inactivated SARS-CoV-2 vaccine × Placebo	18 (Phase I); 26 (Phase II)	Low; Medium; High	>6
ChiCTR2000030750 [47]	Multicenter	120	Randomized	Parallel Assignment	Double	Recombinant chimeric DC vaccine × Blank vaccine	4	NR	25–65
EudraCT 2020-001038-36 [15]	Multicenter	196	Non-randomized	Parallel Assignment	None	BNT162a1 × BNT162b1 × BNT162b2 × BNT162c2	4	Prime/Boost Regimen	18–64
NCT04447781 [24]	Single center	160	Randomized	Sequential Assignment	Triple	INO-4800 (i.d. + EP) × Placebo (i.d. + EP)	4	1 mg/dose + EP; 2 mg/dose + EP (2 times: 0,28)	19–64
NCT04463472 [23]	Single center	30	Non-Randomized	Sequential Assignment	None	AG0301 DNA Vaccine (i.m.)	2	1.0 mg; 2.0 mg (2 times: 0,14)	20–65
CTRI/2020/07/026352 [22]	Single center	1148	Randomized	Sequential Assignment	Single	Novel Corona Virus-2019-nCov vaccine (i.d.) × Placebo (i.d)	NR	0.1 mL (Three times: 0,28,56)	18–55
CTRI/2020/07/026300 NCT04471519 [66]	Multicenter	1125	Randomized	Parallel Assignment	Triple	BBV152A (i.m) × BBV152B (i.m) × BBV152C (i.m.) × Placebo (i.m)	3	0.5 mL (Two times: 0;14)	12–55; 12–65
NCT04470609 [67]	Multicenter	471	Randomized	Parallel Assignment	Quadruple	Inactivated SARS-CoV-2 vaccine × Placebo	4	50 U/0.5 mL; 100 U/0.5 mL (2 times: 0,28)	>60
NCT04473690 [40]	NR	180	Randomized	Parallel Assignment	Quadruple	KBP × Placebo	3	Low and high doses	18–49; 50–70
ChiCTR2000034825 [14]	Multicenter	144	Randomized	Parallel Assignment	NR	BNT162b1 mRNA vaccine × Placebo	6	Low and high doses (2 times: 0,21)	18–55; >55
NCT04449276 EudraCT 2020-001286-36 [16]	Single center	168	Randomized	Sequential Assignment	Single	CVnCoV (i.m. − deltoid muscle) × Placebo (i.m − deltoid muscle)	2	2, 4 and 8 μg (1 and 29)	18–60
NCT04405908 [43]	Single center	150	Randomized	Sequential Assignment	Triple	SCB-2019 vaccine (i.m); SCB-2019 + AS03 (i.m) and SCB-2019 + CpG 1018 + Alum (i.m)	15	3 µg; 9 µg; 30 µg (1,22)	18–54; 55–75
NCT04334980 [26]	Multicenter	84	Randomized	Parallel Assignment	Triple	bacTRL-Spike (oral) × Placebo (oral)	6	1 cfu; 3 cfu; 10 cfu (0)	19–45
NCT04313127 [31]	Single center	108	Non-randomized	Sequential Assignment	None	Ad5-nCoV (i.m)	3	5 × 10¹⁰ vp; 1 × 10¹¹ vp; 1.5 × 10¹¹ vp (Single: 0)	18–60
NCT04299724 [48]	Single center	100	N/A	Single Group Assignment	None	Pathogen-specific aAPC vaccine (s.c)	1	5 × 10⁶ cells (Three times: 0,14,28)	0.5–80
NCT04283461 [17]	Multicenter	155	Non-randomized	Sequential Assignment	None	LNP- encapsulated mRNA-1273 (i.m.)	13	10 mcg; 25 mcg; 50 mcg; 100 mcg; 250 mcg (2 times; 1,29)	18–55; 56–70; >70
NCT04428073 [44]	Single center	32	Non-randomized	Sequential Assignment	None	Covax-19 vaccine	2	1.0 mL of low dose; 1.0 mL of high dose	18–60
ChiCTR2000034112 [13]	Multicenter	168	Randomized	Parallel Assignment	None	mRNA vaccine	3	Low; Medium; High	18–59; 60–80
ChiCTR2000030906 [28]	Multicenter	108	Non-randomized	Parallel Assignment	None	rAd5-nCoV (i.m.)	3	5 × 10¹⁰ vp; 1 × 10¹¹ vp; 1.5 × 10¹¹ vp	18–60
NCT04445194 [39]	Single center	50	Randomized	Parallel Assignment	Double	Recombinant new coronavirus vaccine (CHO cell) (i.m) × Placebo (i.m)	3	25 μg/0.5 mL; 50 μg/0.5 mL	18–59
NCT04453852 [38]	Single center	40	Randomized	Parallel Assignment	Triple	Covax-19 vaccine × Placebo	2	25 ug Spike antigen + 15 mg Advax-2 adjuvant	18–68
ACTRN12620000674932 [37]	Single center	120	Randomized	Parallel Assignment	Triple	SARS-CoV-2 Sclamp vaccine (i.m) × Placebo (i.m)	4	1 × 5 mcg/0.5 mL; 1 × 15 mcg/0.5 mL; 1 × 45 mcg/0.5 mL (2 times: 0,28)	18–55
ISRCTN17072692 [21]	Multicenter	320	Randomized	Sequential Assignment	NR	COVAC mRNA vaccine (i.m. − deltoid muscle)	3	0.1 µg; 0.3 µg; 1.0 µg	18–45; 18–75
NCT04450004 [49]	Multicenter	180	Randomized	Sequential Assignment	None	Coronavirus-like particle COVID-19 vaccine ± CpG 1018 or AS03 (i.m)	9	3.75 µg; 7.5 µg; 15 µg + CpG 1018 or AS03	18–55
NCT04368988 [42]	Multicenter	131	Randomized	Parallel Assignment	Triple	NVX-CoV2373 (Matrix-M) (i.m) × Placebo (i.m)	5	5 μg or 25 μg with/without 50 μg Matrix-M (2 times: 0,21)	18–59
NCT04368728 [18]	Multicenter	7600	Randomized	Parallel Assignment	Triple	BNT162a1 (i.m); BNT162b1 (i.m); BNT162b2 (i.m); BNT162c2 (i.m); Placebo (i.m)	21	0.5 mL (Single or 2 times: 0,21). Prime/boost regimen	18–55; 65–85; 18–85
NCT04336410 [27]	Multicenter	120	Non-randomized	Sequential Assignment	None	INO-4800 (i.d + EP)	3	0.5 mg + EP; 1.0 mg + EP; 2.0 mg + EP (2 times: 0,28)	>18

Open in a new tab

Abbreviations: NR: not reported; MenACWY: meningococcal ACWY licensed control vaccine; mRNA: messenger ribonucleic acid; CHO: Hamster Ovary Cell; rAd26: recombinant adenovirus serotype 26; rAd5-nCoV: recombinant adenovirus serotype 5; GM-CSF: Granulocyte Macrophage-colony Stimulating actor; LV-SMENP-DC: lentiviral minigene vaccine modified with DCs to activate T cells; DCs: dendritic cells; CTLs: cytotoxic T lymphocytes; INO-4800: INOVIO’s DNA vaccine candidate; KBP: Kentucky BioProcessing; AS03: squalene-based immunologic adjuvant made by GlaxoSmithKline (GSK); CpG 1018: cytosine phosphoguanine 1018; Alum: potassium aluminum sulfate; aAPC: artificial antigen presenting cells; LNP: lipid nanoparticle; Matrix-M: matrix-M ^TM adjuvant; i.m.: intramuscular; s.c.: subcutaneous; i.v.: intravenous; i.d.: intradermal; EP: electroporation.

The Canadian bacTRL-Spike-1 vaccine uses a genetically modified probiotic Bifidobacterium longum as a delivery system for a synthetic DNA plasmid encoding S protein to host immune cells in a phase I study; this is the first time that bacTRL has been delivered in humans orally with varied doses in parallel assignment containing 1, 3, or 10 billion colony-forming units [26].

The GX-19 vaccine plasmid in a phase I-II trial in the Republic of Korea by Genexine, Inc. Company (Gyeonggi, Korea) [25] is applied via intramuscular administration in a dose-escalation protocol 28 days apart. A second COVID-19 Indian vaccine ZYCOV-D by Cadila Healthcare Ltd. (also known as Zydus Cadila, Ahmedabad, India) is testing the vaccine in two groups with different age ranges, one from 12 to 55 and another from 12 to 65 years old. In both groups, the doses of 0.5 mL are delivered intramuscularly 14 days apart [22]. The CTP for the Japanese AG0301 DNA vaccine delivers the doses in the same period of time as ZYCOV-D [23], with a population ranging from 20 to 65 years old.

3.3.2. Non-Replicating Viral Vector Vaccines

The second most used platform comprises different serotypes of non-replicating recombinant adenoviral vectors (24%) that comprise the chimpanzee adenoviral vector ChAdOx1 nCoV-19 by Oxford University (Figure 2) [33,34,50,51,52], currently with two in phase II-III [51,52] and another in phase III [50] in the United Kingdom and Brazil, respectively. The adenovirus type 5 (Ad5-nCov) by CanSino Biologics [28,29,30,31,32] targeting the full-length S protein of SARS-CoV-2 displays two studies in phase II in China [29,32].

The Russian Gam-COVID-Vac by Gamaleya Research Institute, which combines Ad5 and a recombinant adenovirus type 26 (Ad26) vectored system targeting the S protein of SARS-CoV-2 [35,36], is in phase I-II. In one of these CTPs, the Gam-COVID-Vac solution is lyophilized [36]. The most advanced ChAdOx1 nCoV-19 protocol is delivered in a single dose of 5 × 10¹⁰ viral particle [50,51], which is being tested two times on days 1 and 28 [51]. A clinical trial divided the groups accordingly to the age of the participants: children ranging from 5 to 12, adults from 18 to 55, and people older than 56 years of age [52]. In turn, the age used in two most advanced Adn5-nCoV CTPs is older than 18, with single doses of 5 × 10¹⁰ and 1 × 10¹¹ in a study with crossover assignment [32] and parallel assignment [29], both with three interventional arms, as shown in Table 2.

3.3.3. Inactivated Virus Vaccines

The inactivated SARS-CoV-2 vaccine was used in 18% of the selected clinical trials (Figure 2) [8,9,10,11,53,54,66,67]. The vaccine developed by SinoVac Biotech Corporation is classified in the CTPs as purified inactivated SARS-CoV-2 and is an adsorbed vaccine. According to preclinical study information, this vaccine, named PiCoVacc, was developed by propagating the CN2 strain of SARS-COV-2 inside VeroCells and inactivated using the chemical agent β-propiolactone [69]. This Chinese vaccine is being tested in Brazil in a phase III study [54] and in a phase III CTP developed in the United Arab Emirates [53]. Another purified inactivated vaccine also propagated SARS-CoV-2 inside VeroCells [8,9,53], but there is no information about the strain or inactivating agent used in pre-clinical studies. A recent phase I-II Indian vaccine BBV152 will apply three inactivated whole-virion strains designated BBV152A, BBV152B, and BBV152C [66]. Another two studies developing purified inactivated SARS-CoV-2 vaccine provides no information about the inactivation processes [12,67]. All these vaccines target multiple proteins of SARS-CoV-2. The most advanced inactivated vaccine (phase III) is applied in two doses 14 days apart in the deltoid muscle [54] in participants of 18 years onwards, as shown in Table 2.

3.3.4. Protein Subunit Vaccines

Vaccines based on the recombinant protein subunit are being tested in 16% of the selected CTPs (Figure 2) [37,38,39,40,41,42,43,44], identified by different names according to their features. The most advanced of them (phase II) apply SARS-CoV-2 protein subunits engineered, produced, and secreted by Chinese Hamster Ovary (CHO) cells [39,41]. Phase I SCB-2019 vaccine is a recombinant SARS-CoV-2 trimeric S protein subunit vaccine, and is tested with or without lipid-based Adjuvant System 03 (AS03) that increases the reaction of the innate immune system, or with a oligonucleotide sequence containing CpG motif (CpG 1018) adjuvants plus aluminum, with a CTP being developed in Australia [43]. Another Australian phase I vaccine is NVX-CoV2373, a recombinant S protein nanoparticle vaccine tested with or without the Novavax saponin-based Matrix M^TM adjuvant [42], COVAX-19^TM, a Vaxine proprietary Advax™ adjuvant technology combined with a recombinant S protein [38,44] and a S protein stabilized using the molecular clamp technology applied with MF59 immunologic adjuvant [37]. A CTP is being developed based on the production of the RBD of S protein through fast-growing tobacco plant technology [40]. The use of adjuvants increases the activity of T and B cells mediated by antigen-presenting cells (APCs) [70].

3.3.5. Dendritic Cells Vaccines

Another 6% of clinical trials (phase I-II) are testing vaccines based on dendritic cells (DC) (Figure 2) [45,46,47]. One of them, from the USA, is testing subcutaneously autologous DC loaded with 1× or 3.33% antigens from SARS-CoV-2 with or without 250 μg or 500 μg of granulocyte-macrophage colony-stimulating factor (GM-CSF), targeting non-specific proteins. This vaccine is developed with the isolation of monocytes from heparinized blood incubated with IL-4 and GM-CSF that are differentiated in vitro in DC, which in turn are incubated with SARS-CoV-2 antigens [46].

China is testing subcutaneously a recombinant chimeric DC vaccine targeting an unspecified SARS-CoV-2 epitope. This vaccine, called LV-SMENP DC, is applied subcutaneously (5 × 10⁶) with intravenous antigen-specific cytotoxic T cells (10⁸). The subjects will be analyzed once a week for four weeks. LV-SMENP DC was developed with a technology that modifies these cells through the lentiviral vector system NHP/TYF [45].

The same lentiviral vector system NHP/TYF was able to modify artificial antigen presentation cells (aAPC) that represent 2% of CTPs [48]. All these lentiviral modified cells encode multiple proteins of SARS-CoV-2, and both CTPs are being developed in China [45,48].

3.3.6. Virus Like Particles Vaccines

Besides this, a phase I study using VLP (2% of the selected CTPs) is recruiting patients in Canada (Figure 2) [49]. This vaccine is administered 21 days apart via intramuscular injection. Each dose is applied to the deltoid region of alternated arms. The doses being tested are initially 3.75 μg in a small number of the population (healthy adults 18 to 55 years of age) with dose-escalation to 7.5 μg and 15 μg unadjuvanted or adjuvanted with either CpG 1018 or AS03, with a follow-up period of six months. After this time, the immunogenicity of the subjects will be tested.

3.4. Trial Progression Rate

The vaccine development clinical trials are displayed by phase, country, and trial progression rate (TPR) according to the beginning and completion date of each study (Table 1) in Figure 3. Most of the clinical trials are in simultaneous phase I-II (46%) [8,9,10,11,12,14,15,19,22,23,24,25,30,33,34,35,36,40,45,46,47,66,67]. In China the TPR ranges from 7.1% to 100% [8,9,10,11,12,14,45,47,67], in Germany the TPR of one study is 94.0% [19], in Russia it is 66.1% [35,36], in the United Kingdom the TPR is 25.25% [34], in Canada the TPR is 18.8% [30], in the USA it is 10.3% [46], in South Africa it is 10.0% [33], in the Republic of Korea the TPR ranges from 3.7% to 5.3% [24,25], in India it ranges from 3.3% to 3.7% [22,66], and in Japan it is 3.3% [23]. Then, of the clinical trials in phase I (34%) [13,16,17,18,21,26,27,28,31,37,38,39,42,43,44,48,49], in China the TPR ranges from 4.8% to 52.0% [13,16,21,26,37,38,44], in the USA it is 45.5% [28], in Canada the TPR ranges from 21.4% to 25.1% [17,27], in Australia the TPR ranges from 5.4% to 14.4% [42,48,49], in Germany it is 13.1% [31], and in the United Kingdom it is 8.8% [18].

Timing clinical trial progress analysis by the phase of study of each clinical trial protocol for active immunization against COVID-19 (vaccine) and the timing progress rate (TPR) according to the initiation and completion date of each study. Note: * the NCT04324606 clinical trial protocol was also registered in the European database for clinical studies with the following identification: EudraCT 2020-001072-15.

Four clinical trials (8%) are in phase II [20,29,32,41]. In China, the trial has a TPR of 35.7%; in the USA, the trial has a TPR of 13.5%; two clinical trials (4%) are in simultaneous phase II-III [51,52] in the United Kingdom, and the studies have a TPR ranging from 18.8% to 30.1%. Four clinical trials (8%) are in phase III [50,53,54,55]. In Brazil, the TPR ranges from 5.5% to 18.9% [50,54]; in the United Arab Emirates, the TPR is 2.7% [53]; and in the USA, the trial has not yet been initiated [55]. Among all clinical trials involving vaccine development, so far only one study (2%) has been completed [10], 56% are recruiting patients [9,11,12,14,16,17,18,19,20,21,22,23,25,27,28,35,36,37,38,39,42,43,45,48,49,50,53,63,66], 30% are not yet recruiting [8,10,13,24,26,30,33,40,41,44,46,47,51,54,55], 6% are active but not recruiting [31,32,34], 4% have not reported their recruitment status [15,52], and 2% have classified their recruitment status as enrolling by invitation [67], as shown in Table 1.

3.5. Study Design of Clinical Trial Protocols

Regarding the clinical trial protocol studies design of vaccination against COVID-19 (Figure 4 and Table 2), 48% of the protocols were multicenter (MC) research trials and 48% were single center (SC); only two CTPs did not report this information. The estimated enrollment of clinical trials in phase III (3%) ranged from 30,000 to 2000 individuals [50]; in phase II-III (6%), there were 10,260 individuals [51,52]; in phase II (9%), it ranged from 500 to 2000 individuals [20,29,32,41]; in phase I-II (47%), it ranged from 30 to 2128 individuals [8,9,10,11,12,14,15,19,22,23,24,25,30,33,34,35,36,40,45,46,47,66,67]; and in phase I (35%), it ranged from 32 to 7600 individuals [13,16,17,18,21,26,27,28,31,37,38,39,42,43,44,48,49,50]. The number of volunteers estimated in each protocol was represented by the scale bar in Figure 4. The CTP intervention design was mostly randomized (76%) and used some type of masking (69%), which varied from 12% single blinding (participant) to 22% double blinding (participant, investigator), 16% triple blinding (participant, investigator, outcomes assessor), and 18% quadruple blinding (participant, care provider, investigator, outcomes assessor). However, certain CTPs have not adopted any techniques for minimizing the bias in allocations and blinding—20% were non-randomized; 4% did not report the strategy of allocation; 28% did not use masking (none), keeping the research open label; 4% did not report the strategy of masking. The intervention model was 60% in parallel-assignment design, following by 32% with sequential assignment design, 4% with single group assignment, 2% with crossover assignment, and 2% did not report the intervention model (Figure 4). The number of intervention arms used in the clinical trial protocols were mainly under 4 (63%), but 22% used between 5 and 10 arms; 6.1% used between 10 and 20; and 8.2% used more than 20 arms of intervention, corresponding to the type of vaccine analyzed according to the different dose concentrations (low, medium, high), the number of doses (single or more than one), and the days of administration (single or double). In addition, the arms were distributed for different ages, including less than 18 years old (8%), more than 18 years old (12%), between 18 and 70 years old (63%), and more than 70 years old (17%).

Study design of vaccine clinical trials against COVID-19 distributed inside out by the different types of allocation, masking, estimated enrollment, rehearsal center, and study countries. The color scale bar represents the number of volunteers estimated in each protocol. Abbreviations: NR—not reported; UK—the United Kingdom; USA—the United States of America.

3.6. Global Research Network in Clinical Trial Protocols

The distribution of vaccine CTP networks between the sponsor and the collaborating institutions is highlighted in the Figure 5 map, focusing mainly on the CTPs collaborating with more than five centers. Among the vaccines leading multicenter CTPs, there is one in the USA controlled by ModernaTX Inc. at phase III (green circle) coordinating 87 collaborating institutions (green cylinders around the red bar of Figure 5), with an estimated enrollment of 30,000 participants, not yet recruited [55] (as detailed in Table 1 and Table 2). In addition, there is another CTP in the USA at phase II (blue circle) recruiting 600 volunteers from 10 centers (blue cylinders of Figure 5) [20]. Two CTPs in Europe are controlled by Oxford University in partnership with AstraZeneca [51,52], coordinating more than 20 collaborating institutions (hospitals, labs, etc., represented by the yellow and purple cylinders in Figure 5) involving approximately 10,260 participants each, at phase II or III (green-blue circle). There is another CTP at phase I-II (red-blue circle) that is recruiting 1090 volunteers at six centers in the United Kingdom [34] (gray cylinders in Figure 5). The CTP in South America is controlled by Butantan Institute in partnership with the Sinovac Life Sciences Co. (Beijing, China) [54], and is at phase III (green circle), coordinating 12 centers in Brazil (dark green cylinders in Figure 5) and recruiting 8870 participants. In Asia, the CTP controlled by Bharat Biotech International Ltd. Is at phase I-II of vaccine development, recruiting 1125 participants in 11 centers in India [66]. In Africa, the vaccine center coordinated by the University of Witwatersrand phase I-II (red-blue circle) is recruiting 2000 volunteers in six centers in South Africa [33]. All these centers leading vaccine multicenter CTPs are highlighted with enlarged figures around the map in Figure 5.

The global distribution of clinical trials by phase (**circles**) that are developing research on vaccines against COVID-19 (**red bar**) in the world and their recruitment centers (**cylinder**). This map displays only the centers that had more than 5 recruitment centers. In particular, the main centers of each continent are arranged around the central map. Phase I (**red circle**), phase I-II (**red-blue circle**), phase II (**blue circle**), phase II-III (**green-blue circle**), and phase III (**green circle**).

However, other centers for vaccines against COVID-19 in development in Europe, Asia, Africa, the Americas, and Oceania are highlighted in the map of Figure 5.

The global distribution of CTPs, according to the execution phase, as shown in Figure 6 and Table A1 at phase I, comprises 17 of 50 (34%) CTPs [13,16,17,18,21,26,27,28,31,37,38,39,42,43,44,48,49]. Among these 17 CTPs, 5 (27.8%) are from China [13,28,31,39,48], 4 (27.8%) are from the USA [17,27,42,44], 2 (11.1%) are from Canada [26,49], 3 (16.7%) are from Australia [37,38,43], 1 (11.1%) is from Germany [16], 1 (5.6%) is from the United Kingdom [21], and one of the CTPs is shared by Germany and the USA [18], as shown in Figure 6A. At phase I-II, there are 23 of 50 (46%) CTPs [8,9,10,11,12,14,15,19,22,23,24,25,30,33,34,35,36,40,45,46,47,66,67]. Among these 23 CTPs, most are in Asia: 9 (41.7%) are from China [8,9,10,11,12,14,45,47,67], 2 are from the Republic of Korea (8.3%) [24,25], 2 are from India (8.3%) [22,66], and 1 is from Japan (4.2%) [23]. Then, in Europe, two are in Eastern Europe from Russia (8.3%) [35,36], two are from Germany (8.3%) [19], and one is from the United Kingdom (4.3%) [34]. In North America, there are three CTPs from the USA (12.5%) [15,30,46]. There is also one from South Africa (4.3%) [33], as shown in Figure 6B. The CTPs in phase II display 4 of 50 (8%) [20,29,32,41], and they are from China (75%) [29,32,41] and the USA (25%) [20], as shown in Figure 6C. There are two phase II-III CTPs out of 50 (4%) [51,52], both located in the United Kingdom (Figure 6D).

Clinical trial distribution by country/continent and phase. (A): CTPs at phase I; (B): CTPs at phase I-II; (C): CTPs at phase II; (D): CTPs at phase II-III; and (E): CTPs at phase III.

However, there are already 4 of 50 (8%) CTPs at phase III [50,53,54,55]. Two of them are in Brazil—one is testing the vaccine developed by the University of Oxford [50] at Universidade Federal de São Paulo (UNIFESP), and other is testing the vaccine developed by Sinovac Life Science Co. at Butantan Institute [54]; one is in the United Arab Emirates, and is testing the vaccine developed by China National Biotec Group Co. at Beijing [53]; and one in the USA, testing the vaccine developed by ModernaTX, Inc. [55], as shown in Figure 6E.

Only 6 of 50 CTPs (12%) comprise a network with other institutions located in different countries. These include the United Kingdom and Brazil [50], China and the United Arab Emirates [53], Canada and China [30], the USA and the Republic of Korea [24], the USA and Australia [42], and Germany and the USA [18]. Four studies do not reveal about their partnerships [15,40,41,44]. The most CTPs (82%) have entered into partnerships with other institutions within the same country.

4. Discussion

Approximately four months after a pandemic was declared by the WHO and more than 640,000 deaths have occurred, a consolidated therapeutic drug strategy protocol approved for COVID-19 still does not exist [71]. At this moment, the epicenter of the outbreak is the American continent, mainly USA and Brazil, and isolation or social distancing remain the central WHO recommendations to avoid infection and increasing numbers of deaths [72].

Unprecedented global initiatives and new partnerships are being established to accelerate the research and development of tests and therapies to control the spread of this pandemic around the world. However, vaccines that mitigate the damage caused by this infectious disease can take much longer to be available with proven safety and efficacy [73]. The time frame for vaccine supply remains uncertain, but to date global labs and industries have registered 50 vaccine CTPs in leading research databases, using eight platforms based on inactivated virus [8,9,10,11,53,54,66,67]; nucleic acid such as mRNA [13,14,15,16,17,18,19,20,55], saRNA [21], and DNA/plasmid [22,23,24,25,26,27]; recombinant adenovirus serotypes platforms, such as adenoviral vector 5 [28,29,30,31,32], chimpanzee adenoviral vector ChAdOx1 [33,34,50,51,52], and combined serotypes vectors Adenovirus 5 and 26 [35,36]; recombinant viral protein subunits [37,38,39,40,41,42,43,44]; modified dendritic cells [45,46,47]; artificial antigen-presenting cells [48]; and VLP vaccine [49]. The advantages and limitations of these platforms will be detailed ahead.

The current landscape of COVID-19 vaccine development shows that most CTPs are being developed in Asia (Table A1). However, regarding former CTPs, only 1 of 4 (15%; [53]) phase III CTPs are located in Asia. There is one CTP recruiting in Abu Dhabi/United Arab Emirates, there is a protocol that was developed in China with an inactivated virus platform, and this protocol was also used in another phase III CTP in Brazil [54]. The virus vector platform vaccine developed in the United Kingdom (Oxford University) is being tested in the most advanced studies (phase II-III), both in the United Kingdom [51,52] and Brazil [50] (phase III). These CTPs (8% of total CTPs) have used the same chimpanzee adenoviral vectored vaccine targeting the S protein of SARS-CoV-2 [50,51,52], in which the recent results show safety and a strong immune response [74,75], but these CTPs differ due to the number of interventional arms testing different vaccine doses (number and concentration), the group age of volunteers, the method of dosing analysis (Abs260, Abs260 corrected for PS80 and qPCR), and other comparisons. Lastly, the mRNA vaccine from Moderna TX, Inc., (Cambridge, MA, USA) is a USA phase III CTP that is the biggest trial, with 30,000 subjects in 87 recruiting centers (Table A1), but the recruiting is just starting [55]. This vaccine platform used advanced technology to improve the drug delivery.

The gold standard for the success of a vaccine is related to its broad and sustained immunogenicity, with adequate safety and efficacy. For this achievement, the antigen delivery systems and their eligibility are important factors [62,76].

Due to the outbreak of COVID-19, it was essential to optimize and reduce the normal stages of the vaccine development process, but possible adverse effects may occur, especially for those belonging to high-risk groups, and this is necessary to take into account during the inclusion period of subjects in these trials [73]. This comprising steps phenomenon is expressed by comprising stages (I-II) [8,9,10,11,12,14,15,19,22,23,24,25,30,33,34,35,36,40,45,46,47,66,67] and (II-III) [51,52] and shortcuts in 50% of the current vaccine CTPs. However, in April, only 5 [17,27,31,45,48] of 50 CTPs were considered the most advanced candidate vaccines to initiate clinical development for (phase I) [73], and none of these CTPs displayed clustered phases in their trials.

On 03 April 2020, Cohen [77] identified eight different vaccine groups or “platforms” in preclinical and clinical development, classified as inactivated or attenuated whole viruses, genetically engineered proteins, and mRNA technology. At that time, the most advanced studies were in phase I. After four months, there are the same eight different vaccine platforms and CTPs (88.3%), which include inactivated virus [8,9,10,11,12], non-replicating viral vectors [28,29,30,31,32], nucleic acids (RNA [13,15,16,17,18,19,20] or DNA [25,26,27]), protein subunits [42,43,44], but now most of these CTPs are in phase II-III or III.

In this review, the non-replicating viral vector was the main technology/platform used (24%). The advantage of the vaccine based on viral vectors is the combined stimulation of the innate and adaptive immune response to the heterologous viral infection and against the antigen expressed by the vector, usually the S protein [78]. The problem related to heterologous response is the previous exposure to some adenovirus serotypes by the human population, leading to a pre-existing anti-vector response, which makes the vector a disadvantage. The use of Ad5 in immunological practice is well established and highly efficient, and exhibits simple manipulation and ease of purification. However, the specific response of the transgene can be mitigated by pre-existing adaptive immune responses to antigenic targets in the vector itself [79]. The previous results of the CTP developed by CanSino confirmed the activation of CD4 and CD8 T cells in the vaccine recipients. However, the vaccine-induced specific antibody or T cell response were partially diminished by the presence of pre-existing anti-Ad5 immunity [80]. On the contrary, the study by Zhu [80] in phase I and the study by Folegatti [75] used an Ad5 vectored COVID-19 vaccine that was very immunogenic, able to induce humoral and cellular responses in most trial participants, and the detectable immune responses was very rapid, with the T cell responses peaking at day 14 after vaccination and the antibodies peaking at day 28.

Therefore, less prevalent adenoviral serotypes, such as Ad35 and Ad26, or primate derivatives, such as chimpanzees, are more often used in vaccine development, as they mimic a natural infection at low risk of herologous response, and stimulate a significant immune response without additional adjuvants [81]. Previous studies using a replication-deficient adenovirus from chimpanzee (ChAdOx1) led to the immunization of BALB/C mice, CD1 mice [82], and rhesus monkeys [83] against MERS-CoV. This adenovirus construct, now encoding the full-length S protein of SARS-COV-2, was able to generate high titers of neutralizing antibodies and a robust CD8 T cell response against this viral protein [82].

DNA or RNA vaccine platforms, also known as synthetic vaccines, were identified in 32% [13,14,15,16,17,18,19,20,55] of the selected CTPs. Vaccines with antigen-encoding DNA/RNA as a platform are relatively versatile, easy to manipulate, and relatively inexpensive to synthesize compared to other types of vaccines. These vaccines have similar strategies of action—for instance, they have coding for the synthesis of target antigens that will be expressed in immune cells. However, the target of each platform is different, in addition to the advantages or risks they present [84].

mRNA based-vaccines provide benefits compared to protein subunits, inactivated or attenuated viruses, and DNA-based vaccines. These benefits were discussed by a study as follows [85]. The first issue is safety, since mRNA is a non-infectious, non-integrating platform, and shows no potential risk of infection or insertional mutagenesis. In addition, mRNA is degraded by regular cellular processes, and its half-life in vivo can be regulated through modifications and delivery methods. The second issue is its efficacy; modifications can make the mRNA more stable and highly translatable. Third, mRNA vaccines have the prospective for fast, inexpensive, and accessible manufacturing due to the high yields of in vitro transcription reactions.

However, this platform is vulnerable in a high mutagenic potential virus [86]. Regarding the SARS-CoV-2 mutagenic potential, a study by Phan [87] revealed many mutations and deletions in coding and non-coding regions, mainly associated with the S protein. Another study [88] identified 11 variations in the SARS-CoV-2 genome which were observed in over 10% of patient isolates from all over the world. Therefore, this topic is still controversial. Nonetheless, this vaccine platform, despite needing adjuvants (other technologies), is more agile and scalable than others. In the selected CTPs, there are seven types of mRNA vaccines: four named BNT162 [14,15,18,19] and three with mRNA1273 [17,20,55], the latter being at a more advanced stage of development. Both types of vaccine consist of LNP encapsulated nucleoside modified mRNA targeting the S protein of SARS-CoV-2. The mRNA-1273 developed by the National Institute of Allergy and Infectious Disease (NIAID) in the USA in collaboration with ModernaTX Inc. [17,20,55] produces the mRNA of S protein in a stable form due to advances in carriers such as LNPs, providing high-efficiency delivery.

Bacteria-derived plasmid-DNA vaccines, in addition to encoding the target antigen, can also encode co-stimulating molecules. These are directed to the nucleus, and need to cross the plasma and nuclear membranes to be activated. Furthermore, they have the possible disadvantage of persistent genomic integration in host cell DNA, leading to subsequent deleterious effects. However, the need for specific delivery systems to achieve good immunogenicity remains a concern. Different methods have been developed to enhance DNA uptake, expression, and immunogenicity (i.e., encapsulation in containing cationic lipids or cholesterol nanoparticles, and adsorption to polymeric or biodegradable nanoparticles), such as the gene gun, needle-free injection devices (jet injection) [89], and in vivo electroporation. This is the case for the INO-4800 vaccine against SARS-CoV-2, currently in clinical trial (phase I) [27], which was administered by intradermal (ID) injection followed by electroporation (EP) using a CELLECTRA^® 2000 device in healthy adult volunteers [27]. The synthesis process of this vaccine involved the alignment of four coding sequences of S protein and the addition of the N-terminal IgE leader sequence. This highly optimized DNA sequence was manufactured and cloned into pGX0001 vector. The resulting plasmids were named pGX9501 and pGX9503 by Inovio Pharmaceuticals [90]. The immunogenicity of INO-4800 was pre-clinically evaluated, and the serum reactivity revealed IgG binding against the S protein of SARS-CoV-2. The serum from INO-4800-immunized BALB/c mice neutralized two SARS-CoV-2 strains—WH-09 (Neutralizing Titer of Antibody (ND50: 97.5) and VIC01 (ND50: 128.1)). In addition, the ND50 of 573.5 was observed in immunized guinea pigs. This study also generated robust S-specific T cell responses in these models, and the detected antibodies were able to block S protein binding to the host ACE2 receptor [90].

Recently (17 June 2020), another DNA vaccine developed in South Korea by Genexine Consortium entered phase I-II clinical trials, in which a preventive GX-19 vaccine will be intramuscularly administrated in healthy volunteers from countries such as Indonesia and Thailand. The company managers expect preliminary data from the initial trial by September 2020 and hope to complete all phases of testing by the end of 2021 [25]. To date, no preclinical studies or technical specifications for the GX-19 vaccine have been released. Hence, DNA and mRNA vaccines are readily designed and can proceed into clinical trials very fast, in addition to outstanding targets for the development of vaccines against SARS-CoV-2 and other related epidemics in the future [91].

Attenuated or inactivated vaccines, known as conventional vaccines, require whole pathogen cultivation and propagation. Thus, it is necessary to obtain a high biosafety level with specialized laboratories and biotechnological tools. Moreover, there is the requirement for lineage cells accepted by regulatory authorities, such as Vero Cells, for the development of industrial-scale inactivated virus vaccines [92]. A total of 18% of the CTPs use inactivated virus vaccine platforms, including a phase III CTP recruiting in Abu Dhabi/the United Arab Emirates [53], and a phase III CTP in Brazil [54]. This approach has been used previously and led to smallpox eradication [93], and vaccines for other diseases such as polio, tetanus, diphtheria, and measles. The clinical trials developed by Sinovac Corporation [10] cultivated the CN2 strain of SARS-CoV-2 in Vero Cells and chemically inactivated them using β-propiolactone. Formaldehyde and UV light are other possible agents for virus inactivation [92]. The process of viral inactivation is delicate and cannot destroy the major virus antigenic structures, which would interfere with their immunogenicity. Depth filtration and optimized steps of chromatography allow vaccine purification [69]. Prior to CTPs, PiCoVacc initiated pre-clinical experiments and administered them with alum adjuvant in BALB/C mice and rhesus macaques, a non-human primate species. This study demonstrated rapid RBD-IgG development, accounting for half of the S protein-induced antibodies produced and possibly the dominant immunogenic part of this protein [69]. Furthermore, no antibody-dependent enhancement (ADE)-mediated vaccine-induced infection aggravation was observed for any vaccinated rhesus macaques [69]. Two other CTPs developed by Chinese Sinopharm Corporation at the Wuhan [8] and Beijing [9] Institutes of Biological Products also expanded SARS-CoV-2 in Vero Cells and are currently in trial. However, no pre-clinical studies or technical specifications of the last two vaccines have been disclosed to date.

Since protein subunit vaccines are restricted to specific epitopes of the virus, most developers have not found proteins other than the S protein used by SARS-CoV-2 to invade cells [94]. Eight clinical trial protocols are analyzing protein subunit vaccines [37,38,39,40,41,42,43,44] combined with different types of adjuvants to help individuals produce an immune response strong enough to protect them from the disease [95]. However, the produced immune responses weaken over time, which means that an individual may require additional shots for booster immunizations throughout their life [94]. The adjuvants used in the selected clinical trial protocols are licensed and approved by the Food and Drug Administration (FDA). The adjuvant CpG1018 increases the body’s immune response; the AS03 enhances the vaccine antigen-specific adaptive immune response; and potassium aluminum sulfate (Alum), one of the agents most used as an adjuvant, acts by creating a deposit at the injection site, thus allowing the slow release of antigen and prolonging the interaction time with APCs, in addition to acting on soluble antigens by converting them into particulate forms that are readily phagocyted [95,96].

The global vaccine R&D efforts against SARS-CoV-2 are unprecedented in terms of scale and speed [73]. From examining all the CTPs operating in the United States (clinicaltrials.gov), China (chictr.org.cn), and Europe (clinicaltrialsregister.eu), it is evident that most COVID-19 vaccine CTP activity is taking place in China, with 19 CTPs (38%). However, the greatest advance has been made in the United Kingdom (Oxford University), in conjunction with several collaborating countries (South Africa and Brazil, among others) and other recruiting centers/institutions in the UK (hospitals, universities, labs, etc.). This CTP has reached phase III protocol [50], and will test 12,000 subjects. On 26 July 2020, its performance was 18.6%. Most CTPs (91.2%) have not collaborated with other external institutions due to the protocol phase; only 6 of 50 (12%) CTPs have reached phase III, for which it is necessary to expand the tests in territories with the outbreak, as seen with the Oxford University protocol, and more recently with Sinovac Life Sciences Co., a Chinese vaccine company. The distribution of collaboration networks between sponsors and the recruiting centers/institutions of the CTPs is strongly concentrated in Asia (23.2%), particularly in Wuhan city, China, where the pandemic started. In Europe and the Americas, the United Kingdom, Brazil, and the USA are the main centers, representing 82% of the global vaccine network or total subjects in vaccine tests. As we discussed earlier, these last countries are now the epicenter of the pandemic. Furthermore, the development of vaccine platforms is occurring more rapidly in wide global networks compared to scientific reports or clinical trial databases. Vaccine developers publish very few clinical trial articles, even regarding the safety or preclinical results.

The pandemic caused by COVID-19 has resulted in increased awareness of global threats to human health, particularly when caused by unknown and emerging pathogens. This pandemic has motivated science and health systems to be prepared for future outbreaks. In addition, global development has begun on vaccine platforms and improvements in public and private health systems to tackle the challenges of new outbreaks. New platforms or approaches, such as viral vectors, protein-like vaccines, and nucleic acids, meet the prerequisites for providing solutions to some of these challenges, representing highly versatile technologies that allow rapid vaccine manufacturing. Each vaccine technology has its own advantages and disadvantages related to its ability to induce certain immune responses, manufacturing capacity, and safety for human use.

5. Conclusions

The race of COVID vaccine remains uncertain, but to date global labs and industries have registered 50 vaccine CTPs in leading research databases, using eight platforms: inactivated virus; nucleic acid, such as mRNA, and DNA/plasmid; recombinant virus vectors; recombinant viral protein subunits; modified dendritic cells; artificial antigen-presenting cell; and VLP vaccine. New groups and laboratories have changed the global vaccine development landscape, especially in Asia. The most advanced Trial does not mean to be the most efficient or safe, the collaborations between countries are still of little significance.

Appendix A

Table A1.

Collaborative research on clinical trial protocols.

ID Number	Phase	Rehearsal Center	Sponsor				Recruiting Centers
ID Number	Phase	Rehearsal Center	Name	City	Country	Region	Name	City	Country	Region
ISRCTN89951424 [50]	III	Single center	University of Oxford (AstraZeneca)	Oxford	United Kingdom	Europe	UNIFESP	Sao Paulo	Brazil	South America
NCT04456595 [54]	III	Multicenter	Butantan Institute (Sinovac Life Sciences Co., Ltd./)	Sao Paulo	Brazil	South America	University of Brasilia	Brasilia	Brazil	South America
							Federal University of Minas Gerais	Belo Horizonte
							Hospital das Clínicas, Federal University of Paraná	Curitiba
							Hospital São Lucas da Pontificia Universidade Catolica do Rio Grande do Sul	Porto Alegre
							Hospital das Clínicas da UNICAMP	Campinas
							Hospital das Clínicas, Faculty of Medicine of Ribeirão Preto, University of São Paulo	Ribeirão Preto
							Emílio Ribas Institute of Infectious Diseases	São Paulo
							Clinical Research Center of the Central Institute of Hospital das Clínicas, Faculty of Medicine, University of São Paulo
							Israeli Institute of Education and Research Albert Einstein
							Municipal University of São Caetano do Sul	São Caetano do Sul
							Medical School of São José do Rio Preto—FAMERP	São José do Rio Preto
							Instituto de Infectologia Evandro Chagas—Fiocruz	Rio de Janeiro
ChiCTR2000034780 [53]	III	Single center	China National Biotec Group Co. Ltd.	Beijing	China	Asia	Shaikh kahlifa Medical City	Abu Dhabi	United Arab Emirates	Asia
NCT04470427 [55]	III	Multicenter	ModernaTX, Inc.	Cambridge	USA	North America	Ascension St. Vincent Birmingham	Birmingham	USA	North America
							Hope Research Institute	Chandler
								Peoria
								Phoenix
							Quality of Life Medical and Research Center	Tucson
							Baptist Health Center for Clinical Research	Little Rock
							Advanced Clinical Research—Rancho Paseo	Banning
							University of California San Diego	La Jolla
							eStudySite - La Mesa	La Mesa
							UCLA Vine Street Clinic CRS	Los Angeles
							Paradigm Clinical Research Institute Inc	Redding
							Benchmark Research—Sacramento	Sacramento
							Medical Center For Clinical Research	San Diego
							University of Colorado Hospital	Aurora
							Lynn Institute of The Rockies	Colorado Springs
							George Washington University	Washington
							Accel Research Site	DeLand
							Research Centers of America	Hollywood
							Jacksonville Center for Clinical Research	Jacksonville
							Suncoast Research Group	Miami
							University of Miami	Miami
							Palm Beach Research Center	West Palm Beach
							Grady Health System	Atlanta
							Children’s Healthcare of Atlanta	Atlanta
							Hope Clinic of The Emory Vaccine Center	Decatur
							Meridian Clinical Research	Savannah
							Clinical Research Atlanta	Stockbridge
							UIC Project WISH CRS	Chicago
							Johnson County Clin-Trials	Lenexa
							Alliance for Multispecialty Research	Newton
							Alliance for Multispecialty Research- East Wichita	Wichita
							Meridian Clinical Research	Baton Rouge
							Benchmark Research - Metairie	Metairie
							University of Maryland School of Medicine	Baltimore
							Meridian Clinical Research	Rockville
							Brigham and Women’s Hospital	Boston
							Henry Ford Health System	Detroit
							MediSync Clinical Research Hattiesburg Clinic	Petal
							Saint Louis University	Saint Louis
							Sundance Clinical Research	Saint Louis
							Meridian Clinical Research	Grand Island
								Norfolk
								Omaha
							Clinical Research Center of Nevada	Las Vegas
							AB Clinical Trials	Las Vegas
							Hackensack University Medical Center	Hackensack
							New Jersey Medical School	Newark
							Meridian Clinical Research	Binghamton
							Weill Cornell Chelsea	New York
							Weill Cornell Medical College	New York
							University of North Carolina at Chapel Hill	Chapel Hill
							Tryon Medical Partners	Charlotte
							Carolina Institute for Clinical Research	Fayetteville
							M3 Wake Research, Inc—M3 Wake	Raleigh
							Trial Management Associates	Wilmington
							Wake Forest University Health Sciences	Winston-Salem
							New Horizons Clinical Research	Cincinnati
							Cincinnati CRS	Cincinnati
							Rapid Medical Research Inc	Cleveland
							Lynn Health Science Institute	Oklahoma
							Crisor	Medford
							Penn Prevention CRS	Philadelphia
							UPMC University Center	Pittsburgh
							Keystone VitaLink Research	Anderson
Greenville
Spartanburg
Coastal Carolina Research Center	Mount Pleasant
Meridian Clinical Research	Dakota Dunes
WR-ClinSearch	Chattanooga
Alliance for Multispecialty Research	Knoxville
Vanderbilt University Medical Center	Nashville
Benchmark Research	Austin
Tekton Research	Austin
Advanced Clinical Research—Be Well MD	Cedar Park
Global Medical Research—M3 Wake Research	Dallas
Benchmark Research	Fort Worth
University of Texas Medical Branch	Galveston
Baylor College of Medicine	Houston
DM Clinical Research—Texas Center For Drug Development	Houston
Laguna Clinical Research	Laredo
Centex Studies	McAllen
Benchmark Research	San Angelo
Clinical Trials of Texas, Inc	San Antonio
DM Clinical Research	Tomball
Foothill Family Clinic - North	Salt Lake City
Foothill Family Clinic-South Clinic	Salt Lake City
Kaiser Permanente	Seattle
NCT04400838 [51]	II-III	Multicenter	University of Oxford (AstraZeneca)	Oxford	United Kingdom	Europe	University Hospital Southampton NHS Foundation Trust	Southampton	United Kingdom	Europe
							St Georges University Hospital NHS Foundation Trust	London
							University Hospitals Birmingham NHS Foundation Trust	Birmingham
							University Hospitals Bristol and Weston NHS Foundation Trust	Bristol
							North Bristol NHS Trust	Bristol
							NIHR Cambridge Clinical Research Facility	Cambridge
							Public Health Wales	Cardiff
							Castle Hill Hospital	Cottingham
							NHS Lothian, Western General Hospital	Edinburgh
							Glasgow University and NHS Greater Glasgow & Clyde, New Lister Building, Glasgow Royal Infirmary & Queen Elizabeth University Hospital	Glasgow
							Liverpool School of Tropical Medicine (LSTM), Accelerator Research Clinic. Clinical Sciences Accelerator	Liverpool
							London North West University Healthcare Trust (LNWUH), Northwick Park Hospital	London
							University College London Hospitals NHS Foundation Trust	London
							Guy’s and St Thomas’ NHS Foundation Trust, Department of Infection, St Thomas Hospital	London
							Imperial College Healthcare NHS Trust	London
							The Newcastle upon Tyne Hospitals NHS Foundation Trust, Royal Victoria Infirmary	Newcastle
							University of Nottingham Health Service, Cripps Health Centre, University Park	Nottingham
							CCVTM, University of Oxford, Churchill Hospital	Oxford
							John Radcliffe Hospital	Oxford
							Sheffield Teaching Hospitals, Royal Hallamshire Hospital	Sheffield
EudraCT2020-001228-32 ISRCTN90906759 [52]	II-III	Multicenter	University of Oxford (AstraZeneca)	Oxford	United Kingdom	Europe	Centre for Clinical Vaccinology & Tropical Medicine	Oxford	United Kingdom	Europe
							University Hospital Southampton NHS Foundation Trust	Southampton
							NIHR Imperial Clinical Research Facility	London
							St Georges University Hospital NHS Foundation Trust	London
							University Hospitals Bristol and Weston NHS Foundation Trust	Bristol
							North Bristol NHS Trust	Bristol
							University of Nottingham Health Service	Nottingham
							Sheffield Teaching Hospitals	Sheffield
							University Hospitals Birmingham NHS Foundation Trust (UHB)	Birmingham
							Wales (Public Health Wales)	Newport
							Greater Glasgow and Clyde NHS Board	Glasgow
							Guy’s and St Thomas’ NHS Foundation Trust	London
							Liverpool School of Tropical Medicine	Liverpool
							The Newcastle upon Tyne Hospitals NHS Foundation Trust	Newcastle upon Tyne
							University College London Hospital (UCLH)	London
							NHS Lothian	Edinburgh
							NIHR Cambridge Clinical Research Facility	Cambridge
							Oxford University Hospital Foundation Trust	Oxford
							Nottingham University Hospitals NHS Trust	Nottingham
							Hull University Teaching Hospitals NHS Trust (HUTH)	Hull
							Northwick Park Hospital	London
NCT04405076 [20]	II	Multicenter	ModernaTX, Inc.	Cambridge	USA	North America	Meridian Clinical Research	Savannah	USA	North America
							Heartland Research Associates	Newton
							Heartland Research Associates	Kansas City
							Meridian Clinical Research	Norfolk
							Meridian Clinical Research	Omaha
							Trial Management Associates	Wilmington
							Meridian Clinical Research	Dakota Dunes
							Benchmark Research	Austin
							Benchmark Research	San Angelo
							Advanced Clinical Research/Velocity	West Jordan
NCT04341389 [32]	II	Single center	Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China	Shanghai	China	Asia	Hubei Provincial Center for Disease Control and Prevention	Wuhan	China	Asia
ChiCTR2000031781 [29]	II	Multicenter	Jiangsu Provincial Center for Disease Control and Prevention (CanSino Biological Inc.)	Nanjing	China	Asia	Wuhan Rest Center, Chinese People’s Armed Police Force	Wuhan	China	Asia
							Hubei Provincial Center for Disease Control and Prevention
							Zhongnan Hospital of Wuhan University
NCT04466085 [41]	II	NR	Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.	Beijing	China	Asia	NR	NR	NR	NR
NCT04445389 [25]	I, II	Single center	Genexine, Inc.	Seongnam	Republic of Korea	Asia	Severance hospital	Seoul	Republic of Korea	Asia
NCT04444674 [33]	I, II	Multicenter	University of Witwatersrand	Johannesburg	South Africa	Africa	PHRU Kliptown	Johannesburg	South Africa	Africa
							Wits RHI Shandukani Research Center	Johannesburg
							Setshaba Research Centre (SRC)	Soshanguve
							Chris Hani Baragwanath Academic Hospital—DST/NRF VPD RMPRU	Soweto
							FAMCRU	Cape Town
							Groote Schuur hospital, Lung infection and immunity unit, UCT	Cape Town
NCT04437875 [36]	I, II	Single center	Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation	Moscow	Russia	Europe	Sechenov First Moscow State Medical University	Moscow	Russia	Europe
NCT04436471 [35]	I, II	Single center	Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation	Moscow	Russia	Europe	Main military clinical hospital named after academician N. N. Burdenko	Moscow	Russia	Europe
NCT04412538 [12]	I, II	Single center	Chinese Academy of Medical Sciences	Beijing	China	Asia	West China Second University Hospital	Sichuan	China	Asia
NCT04398147 [30]	I, II	Single center	CanSino Biologics Inc.	Tianjin	China	Asia	Canadian Center for Vaccinology	Halifax	Canada	North America
NCT04386252 [46]	I, II	Single center	Aivita Biomedical, Inc.	Irvine	USA	North America	Hoag Memorial Hospital Presbyterian	Newport Beach	USA	North America
NCT04383574 [10]	I, II	Single center	Sinovac Research and Development Co. Ltd.	Beijing	China	Asia	Renqiu City Center for Disease Control and Prevention	Renqiu	China	Asia
NCT04380701 [19]	I, II	Single center	Biontech RNA Pharmaceuticals GmbH	Berlin	Germany	Europe	Contract Research Organization	Berlin	Germany	Europe
NCT04352608 [11]	I, II	Single center	Sinovac Research and Development Co. Ltd.	Beijing	China	Asia	Suining County Center for Disease Control and Prevention	Xuzhou	China	Asia
NCT04324606 EudraCT2020-001072-15 [34]	I, II	Multicenter	University of Oxford (AstraZeneca)	Oxford	United Kingdom	Europe	University Hospital Southampton NHS Foundation Trust	Southampton	United Kingdom	Europe
							University Hospitals Bristol and Weston NHS Foundation Trust	Bristol
							St Georges University Hospital NHS Foundation Trust	London
							Imperial College Healthcare NHS Trust	London
							CCVTM, University of Oxford, Churchill Hospital	Oxford
							John Radcliffe Hospital	Oxford
NCT04276896 [45]	I, II	Multicenter	Shenzhen Geno-Immune Medical Institute	Shenzhen	China	Asia	Shenzhen Geno-Immune Medical Institute	Shenzhen	China	Asia
							Shenzhen Third People’s Hospital
							Shenzhen Second People’s Hospital
ChiCTR2000032459 [9]	I, II	Single-center	Henan Provincial Center for Disease Control and Prevention (Sinopharm)	Zhengzhou	China	Asia	Liangyuan district centers for disease control and prevention	Shangqiu	China	Asia
ChiCTR2000031809 [8]	I, II	Multicenter	Henan Provincial Center for Disease Control and Prevention (Sinopharm)	Zhengzhou	China	Asia	Wuzhi County Center for Disease Control and Prevention	Jiaozuo	China	Asia
ChiCTR2000031809 [8]	I, II	Multicenter		Zhengzhou	China	Asia	People’s hospital, Wuzhi county	Jiaozuo	China	Asia
ChiCTR2000030750 [47]	I, II	Multicenter	Shenzhen Third People’s Hospital	Shenzhen	China	Asia	Shenzhen Third People’s Hospital	Shenzhen	China	Asia
ChiCTR2000030750 [47]	I, II	Multicenter	Shenzhen Third People’s Hospital	Shenzhen	China	Asia	Shenzhen People’s Hospital	Shenzhen	China	Asia
EudraCT 2020-001038-36 [15]	I, II	Multicenter	BioNTech RNA Pharmaceuticals GmbH (Fosun Pharma/Pfizer)	Mainz	Germany	Europe	NR	NR	NR	NR
NCT04447781 [24]	I, II	Single center	International Vaccine Institute	Seoul	Republic of Korea	Asia	Seoul National University Hospital	Seoul	Republic of Korea	Asia
NCT04447781 [24]	I, II	Single center	Inovio Pharmaceuticals	San Diego	USA	North America	Seoul National University Hospital	Seoul	Republic of Korea	Asia
NCT04463472 [23]	I, II	Single center	AnGes, Inc.	Osaka	Japan	Asia	Osaka City University Hospital	Osaka	Japan	Asia
CTRI/2020/07/026352 [22]	I, II	Single center	Cadila Healthcare Ltd.	Ahmedabad	India	Asia	Zydus Research Center	Ahmedabad	India	Asia
CTRI/2020/07/026300 NCT04471519 [66]	I, II	Multicenter	Bharat Biotech International Ltd.,	Medchal	India	Asia	All India Institute of Medical Sciences	Patna	India	Asia
							All India Institute of Medical Sciences	New Delhi
							Gillukar Multispeciality Hospital	Nagpur
							Institute of Medical Sciences and SUM Hospital	Jajapur
							Jeevan Rekha Hospital	Begaum
							King George Hospital	Visakhapatnam
							Nizam’s Institute of Medical Sciences	Hyderabad
							PGIMS	Rohtak
							Prakhar Hospital	Knapur Nagar
							Rana Hospital and Trauma Center	Gorakhpur
							Redkar Hospital and Research Center	North Goa
							SRM Hospital & Research Center	Kancheepuram
NCT04470609 [67]	I, II	Multicenter	Chinese Academy of Medical Sciences	Beijing	China	Asia	West China Second University Hospital	Sichuan	China	Asia
NCT04470609 [67]	I, II	Multicenter	Chinese Academy of Medical Sciences	Beijing	China	Asia	West China women’s and children’s Hospital	Sichuan	China	Asia
NCT04473690 [40]	I, II	NR	Kentucky BioProcessing, Inc.	Owensboro	USA	North America	NR	NR	NR	NR
ChiCTR2000034825 [14]	I, II	Multicenter	Jiangsu Provincial Center for Disease Prevention and Control	Nanjung	China	Asia	China Medical City, the Vaccine Engineering Center	Jiangsu	China	Asia
							Taizhou Center for Disease Control and Prevention
							Taizhou People’s Hospital
NCT04449276 2020-001286-36 [16]	I	Single center	CureVac AG	Tübingen	Germany	Europe	University Hospital Tübingen Institut für Tropenmedizin	Tübingen	Germany	Europe
NCT04405908 [43]	I	Single center	Clover Biopharmaceuticals AUS Pty Ltd. (GSK/Dynavax)	Perth	Australia	Oceania	Linear Clinical Research Ltd.	Nedlands	Australia	Oceania
NCT04334980 [26]	I	Multicenter	Symvivo Corporation	British Columbia	Canada	North America	Vaccine Evaluation Center, BC Children’s Hospital Research Institute, University of British Columbia	Vancouver	Canada	North America
NCT04334980 [26]	I	Multicenter	Symvivo Corporation	British Columbia	Canada	North America	Canadian Center for Vaccinology Dalhousie University, IWK Health Centre	Halifax	Canada	North America
NCT04313127 [31]	I	Single center	CanSino Biologics Inc.	Tianjin	China	Asia	Hubei Provincial Center for Disease Control and Prevention	Wuhan	China	Asia
NCT04299724 [48]	I	Single center	Shenzhen Geno-Immune Medical Institute	Shenzhen	China	Asia	Shenzhen Geno-Immune Medical Institute	Shenzhen	China	Asia
NCT04283461 [17]	I	Multicenter	National Institute of Allergy and Infectious Diseases (NIAID) (ModernaTX, Inc.)	Bethesda	USA	North America	Emory Vaccine Center—The Hope Clinic	Decatur	USA	North America
							National Institutes of Health - Clinical Center - Vaccine Research Center Clinical Trials Program	Bethesda
							Kaiser Permanente Washington Health Research Institute—Vaccines and Infectious Diseases	Seattle
NCT04428073 [44]	I	Single center	GeneCure Biotechnologies	Nercross	USA	North America	NR	NR	NR	NR
ChiCTR2000034112 [13]	I	Multicenter	Shulan (Hangzhou) Hospital;	Hangzhou	China	Asia	Shulan (Hangzhou) Hospital	Hangzhou	China	Asia
ChiCTR2000034112 [13]	I	Multicenter	Center for Disease Control and Prevention of Guangxi Zhuang Autonomous Region	Beijing	China	Asia	Yongfu County Center for Disease Control and Prevention	NR	China	Asia
ChiCTR2000030906 [28]	I	Multicenter	Jiangsu Provincial Center for Disease Control and Prevention (CanSino Biological Inc.)	Nanjing	China	Asia	Wuhan Rest Center, Chinese People’s Armed Police Force	Wuhan	China	Asia
ChiCTR2000030906 [28]	I	Multicenter		Nanjing	China	Asia	Tongji Hospital	Wuhan	China	Asia
NCT04445194 [39]	I	Single center	Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.	Beijing	China	Asia	The Second Affiliated Hospital of Chongqing Medical University	Chongqing	China	Asia
NCT04453852 [38]	I	Single center	Vaxine Pty Ltd./Medytox	Adelaide	Australia	Oceania	PARC Clinical Research	Adelaide	Australia	Oceania
ACTRN12620000674932 [37]	I	Single center	Univerty of Queensland/CSL/Seqirus	St Lucia	Australia	Oceania	Q-Pharm Pty—Clive Berghofer Research Centre (CBCRC)	Herston	Australia	Oceania
ISRCTN17072692 [21]	I	Multicenter	Imperial College London	London	United Kingdom	Europe	NIHR Imperial Clinical Research Facility	London	United Kingdom	Europe
							Surrey Clinical Research Facility	Surrey
							University Hospital Southampton	Hampshire
							St. George’s Hospital	London
NCT04450004 [49]	I	Multicenter	Medicago Inc.	Quebec	Canada	North America	Syneos Health	Montreal	Canada	North America
NCT04450004 [49]	I	Multicenter	Medicago Inc.	Quebec	Canada	North America	Syneos Health	Quebec	Canada	North America
NCT04368988 [42]	I	Multicenter	Novavax, Inc.	Maryland	USA	North America	Investigational Research Site 1	Herston	Australia	Oceania
NCT04368988 [42]	I	Multicenter	Novavax, Inc.	Maryland	USA	North America	Investigational Research Site 2	Melbourne	Australia	Oceania
NCT04368728 [18]	I	Multicenter	Biontech SE	Berlin	Germany	Europe	University of Maryland, Center for Vaccine Development and Global Health	Baltimore	USA	North America
			Biontech SE	Berlin	Germany	Europe	NYU Langone Health	New York
			Pfizer (Fosun Pharma)	New York	USA	North America	Rochester Regional Health/Rochester General Hospital	Rochester
			Pfizer (Fosun Pharma)	New York	USA	North America	Cincinnati Children’s Hospital Medical Center	Cincinnati
NCT04336410 [27]	I	Multicenter	Inovio Pharmaceuticals	San Diego	USA	North America	Central Kentucky Research Associates	Lexington	USA	North America
							Center for Pharmaceutical Research	Kansas City
							University of Pennsylvania	Philadelphia

Open in a new tab

Abbreviation: GSK: GlaxoSmithKline; NIAID: National Institute of Allergy and Infectious Diseases; USA: United States of America; UNIFESP: Universidade Federal de São Paulo; UNICAMP: Universidade Estadual de Campinas; NHS: National Health Service; LSTM: Liverpool School of Tropical Medicine; LNWUH: London North West University Healthcare Trust; CCVTM: Centre for Clinical Vaccinology and Tropical Medicine; NIHR—National Institute for Health Research; UHB: University Hospitals Birmingham; UCLH: University College London; HUTH: Hull University Teaching Hospitals; NR: Not reported; PHRU: Perinatal HIV Research Unit; Wits RHI: Wits Reproductive Health and HIV Institute; SRC: Setshaba Research Centre; RMPRU: Respiratory and Meningeal Pathogens Research Unit; DST: Department of Science and Technology; NRF: National Research Foundation; VPD: Vaccine Preventable Diseases; FAMCRU: Family Centre for Research with Ubuntu; UCT: UCT Lung Institute; PGIMS: Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences; CBCRC: Clive Berghofer Research Centre; NIHR: National Institute for Health Research.

Author Contributions

Conceptualization, G.N.A.R., M.P.N., A.H.A., F.A.O., and L.F.G.; methodology, G.N.A.R., M.P.N., L.P.N., and L.F.G.; validation, G.N.A.R., M.P.N., L.C.M., and L.F.G.; formal analysis, G.N.A.R., M.P.N., A.H.A., F.A.O., J.B.M., and L.F.G.; investigation, G.N.A.R., M.P.N., A.H.A., F.A.O., L.C.M., L.P.N., J.B.M., and L.F.G.; resources, L.F.G.; data curation, L.F.G.; writing—original draft preparation, G.N.A.R., M.P.N., A.H.A., L.C.M., L.P.N., and L.F.G.; writing—review and editing, G.N.A.R., M.P.N., L.C.M., L.P.N., and L.F.G.; visualization, G.N.A.R., M.P.N., A.H.A., F.A.O., J.B.M., and L.F.G.; supervision, L.F.G.; project administration, L.F.G.; funding acquisition, L.F.G. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by CNPq (400856/2016-6), INCT-FCx:FAPESP (2014/50983-3), and SisNANO2.0. (442539/2019-3).

Conflicts of Interest

The authors declare no conflict of interest.

References

1.Hamed M.A. An overview on COVID-19: Reality and expectation. Bull. Natl. Res. Cent. 2020;44:86. doi: 10.1186/s42269-020-00341-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
2.Worldometer COVID-19 Pandemic Data Update. [(accessed on 27 July 2020)];2020 Available online: https://www.worldometers.info/coronavirus/
3.Zhu F.C., Guan X.H., Li Y.H., Huang J.Y., Jiang T., Hou L.H., Li J.X., Yang B.F., Wang L., Wang W.J., et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020 doi: 10.1016/S0140-6736(20)31605-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
4.Zhang T., He Y., Xu W., Ma A., Yang Y., Xu K.F. Clinical trials for the treatment of Coronavirus disease 2019 (COVID-19): A rapid response to urgent need. Sci. China Life Sci. 2020;63:774–776. doi: 10.1007/s11427-020-1660-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
5.Md Insiat Islam R. Current Drugs with Potential for Treatment of COVID-19: A Literature Review. J. Pharm. Pharm. Sci. 2020;23:58–64. doi: 10.18433/jpps31002. [DOI] [PubMed] [Google Scholar]
6.Savioli F. Is there a rationale for heparin use among severe COVID-19 patients? Einstein. 2020;18:eED5758. doi: 10.31744/einstein_journal/2020ED5758. [DOI] [PMC free article] [PubMed] [Google Scholar]
7.Osama El-Gendy A., Saeed H., Ali A.M.A., Zawbaa H.M., Gomaa D., Harb H.S., Madney Y.M., Osama H., Abdelrahman M.A., Abdelrahim M.E.A. Bacillus Calmette–Guérin vaccine, antimalarial, age and gender relation to COVID-19 spread and mortality. Vaccine. 2020;38:5564–5568. doi: 10.1016/j.vaccine.2020.06.083. [DOI] [PMC free article] [PubMed] [Google Scholar]
8.ChiCTR2000031809 A Randomized, Double-Blind, Placebo Parallel-Controlled Phase I/II Clinical Trial for Inactivated Novel Coronavirus Pneumonia Vaccine (Vero Cells) [(accessed on 27 July 2020)];2020 Available online: http://www.chictr.org.cn/hvshowproject.aspx?id=27698.
9.ChiCTR2000032459 A Phase I/II Clinical Trial for Inactivated Novel Coronavirus (2019-CoV) Vaccine (Vero Cells) [(accessed on 27 July 2020)];2020 Available online: http://www.chictr.org.cn/showprojen.aspx?proj=53003.
10.Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19) [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04383574.
11.Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19) [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04352608.
12.Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04412538.
13.ChiCTR2000034112 A Phase I Clinical Trial to Evaluate the Safety, Tolerance and Preliminary Immunogenicity of Different Doses of a SARS-CoV-2 mRNA Vaccine in Population Aged 18-59 Years and 60 Years and Above. [(accessed on 27 July 2020)];2020 Available online: http://www.chictr.org.cn/hvshowproject.aspx?id=40018.
14.ChiCTR2000034825 A Phase I clinical trial of novel coronavirus pneumonia (COVID-19) mRNA Vaccine (BNT162b1) in China 2020. [(accessed on 27 July 2020)];2020 Available online: http://www.chictr.org.cn/showprojen.aspx?proj=56834.
15.EUCTR 2020-001038-36-DE Study to Investigate the Safety and Effects of Vaccines in Healthy Adults. [(accessed on 27 July 2020)];2020 Available online: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001038-36.
16.A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04449276.
17.Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19) [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04283461.
18.Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04368728.
19.A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04380701.
20.Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04405076.
21.ISRCTN17072692 Clinical Trial to Assess the Safety of a Coronavirus Vaccine in Healthy Men and Women. [(accessed on 27 July 2020)];2020 Available online: http://www.isrctn.com/ISRCTN17072692.
22.CTRI/2020/07/026352 Novel Corona Virus-2019-nCov Vaccine by Intradermal Route in Healthy Subjects. [(accessed on 27 July 2020)];2020 Available online: http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45306.
23.Study of COVID-19 DNA Vaccine (AG0301-COVID19) [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04463472.
24.Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04447781.
25.Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04445389.
26.Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04334980.
27.Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04336410.
28.ChiCTR2000030906 A Phase I Clinical Trial for Recombinant Novel Coronavirus (2019-COV) Vaccine (Adenoviral Vector) [(accessed on 27 July 2020)];2020 Available online: http://www.chictr.org.cn/hvshowproject.aspx?id=24074.
29.ChiCTR2000031781 A Randomized, Double-Blinded, Placebo-Controlled Phase II Clinical Trial for Recombinant Novel Coronavirus (2019-nCOV) Vaccine (Adenovirus Vector) [(accessed on 27 July 2020)];2020 Available online: http://www.chictr.org.cn/showprojen.aspx?proj=52006.
30.Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04398147.
31.Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04313127.
32.A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector) [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04341389.
33.COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04444674.
34.A Study of a Candidate COVID-19 Vaccine (COV001) [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04324606.
35.Development An Open Study of the Safety, Tolerability and Immunogenicity of the Drug “Gam-COVID-Vac” Vaccine Against COVID-19. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04436471.
36.Development An Open Study of the Safety, Tolerability and Immunogenicity of “Gam-COVID-Vac Lyo” Vaccine Against COVID-19. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04437875.
37.ACTRN12620000674932 An Interventional Study to Evaluate the Safety and Immune Response of a Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2, the Virus that Causes COVID-19 Infection) when Given to Healthy Adult Participants. [(accessed on 27 July 2020)];2020 Available online: http://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000674932.
38.Monovalent Recombinant COVID19 Vaccine. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04453852.
39.Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04445194.
40.KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04473690.
41.Clinical Study of Recombinant Novel Coronavirus Vaccine. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04466085.
42.Novavax Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04368988.
43.SCB-2019 as COVID-19 Vaccine. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04405908.
44.Therapeutic Vaccine Trial of COVID-19 for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04428073.
45.Immunity and Safety of Covid-19 Synthetic Minigene Vaccine. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04276896.
46.Phase Ib-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04386252.
47.ChiCTR2000030750 A Clinical Study for Effectiveness and Safety Evaluation for Recombinant Chimeric COVID-19 Epitope DC Vaccine in the Treatment of Novel Coronavirus Pneumonia. [(accessed on 27 July 2020)];2020 Available online: http://www.chictr.org.cn/showproj.aspx?proj=50928.
48.Safety and Immunity of Covid-19 aAPC Vaccine. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04299724.
49.Medicago Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04450004.
50.ISRCTN89951424 A Phase III Study to Investigate a Vaccine Against COVID-19. [(accessed on 27 July 2020)];2020 Available online: http://www.isrctn.com/ISRCTN90853814:2020.
51.Investigating a Vaccine Against COVID-19. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04400838.
52.EUCTR2020-001228-32-GB Investigating a Vaccine Against COVID-19. [(accessed on 27 July 2020)];2020 Available online: https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001228-32/GB.
53.ChiCTR2000034780 A Phase III Clinical Trial for Inactivated Novel Coronavirus Pneumonia (COVID-19) Vaccine (Vero Cells) [(accessed on 27 July 2020)];2020 Available online: http://www.chictr.org.cn/hvshowproject.aspx?id=43780.
54.Clinical Trial of Efficacy and Safety of Sinovac’s Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04456595.
55.A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04470427.
56.Nasrollahzadeh M., Sajjadi M., Soufi G.J., Iravani S., Varma R.S. Nanomaterials and Nanotechnology-Associated Innovations against Viral Infections with a Focus on Coronaviruses. Nanomaterials. 2020;10:1072. doi: 10.3390/nano10061072. [DOI] [PMC free article] [PubMed] [Google Scholar]
57.Itani R., Tobaiqy M., Al Faraj A. Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients. Theranostics. 2020;10:5932–5942. doi: 10.7150/thno.46691. [DOI] [PMC free article] [PubMed] [Google Scholar]
58.Wang F., Kream R.M., Stefano G.B. An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development. Med. Sci. Monit. 2020;26:e924700. doi: 10.12659/MSM.924700. [DOI] [PMC free article] [PubMed] [Google Scholar]
59.Wadman M. Antivaccine forces gaining online. Science. 2020;368:699. doi: 10.1126/science.368.6492.699. [DOI] [PubMed] [Google Scholar]
60.Pagliusi S., Jarrett S., Hayman B., Kreysa U., Prasad S.D., Reers M., Hong Thai P., Wu K., Zhang Y.T., Baek Y.O., et al. Emerging manufacturers engagements in the COVID −19 vaccine research, development and supply. Vaccine. 2020;38:5418–5423. doi: 10.1016/j.vaccine.2020.06.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
61.Hodgson J. The pandemic pipeline. Nat. Biotechnol. 2020;38:523–532. doi: 10.1038/d41587-020-00005-z. [DOI] [PubMed] [Google Scholar]
62.Amanat F., Krammer F. SARS-CoV-2 Vaccines: Status Report. Immunity. 2020;52:583–589. doi: 10.1016/j.immuni.2020.03.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
63.Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04332835.
64.Selçuk A.A. A Guide for Systematic Reviews: PRISMA. Turk. Arch. Otorhinolaryngol. 2019;57:57–58. doi: 10.5152/tao.2019.4058. [DOI] [PMC free article] [PubMed] [Google Scholar]
65.WHO DRAFT Landscape of COVID-19 Candidate Vaccines. [(accessed on 30 June 2020)]; Available online: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
66.Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04471519.
67.Prevention Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged ⩾60 Years. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04470609.
68.Rees V. Germany to Begin First Clinical Trial of COVID-19 Vaccine Candidate. [(accessed on 30 June 2020)]; Available online: https://www.europeanpharmaceuticalreview.com/news/117624/germany-to-begin-first-clinical-trial-of-covid-19-vaccine-candidate/
69.Gao Q., Bao L., Mao H., Wang L., Xu K., Yang M., Li Y., Zhu L., Wang N., Lv Z., et al. Rapid development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020 doi: 10.1126/science.abc1932. [DOI] [PMC free article] [PubMed] [Google Scholar]
70.Chen X., Han W., Wang G., Zhao X. Application prospect of polysaccharides in the development of anti-novel coronavirus drugs and vaccines. Int. J. Biol. Macromol. 2020;164:331–343. doi: 10.1016/j.ijbiomac.2020.07.106. [DOI] [PMC free article] [PubMed] [Google Scholar]
71.Jean S.S., Lee P.I., Hsueh P.R. Treatment options for COVID-19: The reality and challenges. J. Microbiol. Immunol. Infect.—Wei mian yu gan ran za zhi. 2020;53:436–443. doi: 10.1016/j.jmii.2020.03.034. [DOI] [PMC free article] [PubMed] [Google Scholar]
72.Shadmi E., Chen Y., Dourado I., Faran-Perach I., Furler J., Hangoma P., Hanvoravongchai P., Obando C., Petrosyan V., Rao K.D., et al. Health equity and COVID-19: Global perspectives. Int. J. Equity Health. 2020;19:104. doi: 10.1186/s12939-020-01218-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
73.Thanh Le T., Andreadakis Z., Kumar A., Gómez Román R., Tollefsen S., Saville M., Mayhew S. The COVID-19 vaccine development landscape. Nat. Rev. Drug Discov. 2020;19:305–306. doi: 10.1038/d41573-020-00073-5. [DOI] [PubMed] [Google Scholar]
74.Tan W.G., Jin H.T., West E.E., Penaloza-MacMaster P., Wieland A., Zilliox M.J., McElrath M.J., Barouch D.H., Ahmed R. Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors. J. Virol. 2013;87:1359–1372. doi: 10.1128/JVI.02055-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
75.Folegatti P.M., Ewer K.J., Aley P.K., Angus B., Becker S., Belij-Rammerstorfer S., Bellamy D., Bibi S., Bittaye M., Clutterbuck E.A., et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020 doi: 10.1016/S0140-6736(20)31604-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
76.Afrough B., Dowall S., Hewson R. Emerging viruses and current strategies for vaccine intervention. Clin. Exp. Immunol. 2019;196:157–166. doi: 10.1111/cei.13295. [DOI] [PMC free article] [PubMed] [Google Scholar]
77.Cohen J. Vaccine designers take first shots at COVID-19. Science. 2020;368:14–16. doi: 10.1126/science.368.6486.14. [DOI] [PubMed] [Google Scholar]
78.Ura T., Okuda K., Shimada M. Developments in Viral Vector-Based Vaccines. Vaccines. 2014;2:624–641. doi: 10.3390/vaccines2030624. [DOI] [PMC free article] [PubMed] [Google Scholar]
79.Ewer K.J., Lambe T., Rollier C.S., Spencer A.J., Hill A.V., Dorrell L. Viral vectors as vaccine platforms: From immunogenicity to impact. Curr. Opin. Immunol. 2016;41:47–54. doi: 10.1016/j.coi.2016.05.014. [DOI] [PubMed] [Google Scholar]
80.Zhu F.C., Li Y.H., Guan X.H., Hou L.H., Wang W.J., Li J.X., Wu S.P., Wang B.S., Wang Z., Wang L., et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395:1845–1854. doi: 10.1016/S0140-6736(20)31208-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
81.Klug B., Robertson J.S., Condit R.C., Seligman S.J., Laderoute M.P., Sheets R., Williamson A.L., Gurwith M., Kochhar S., Chapman L., et al. Adventitious agents and live viral vectored vaccines: Considerations for archiving samples of biological materials for retrospective analysis. Vaccine. 2016;34:6617–6625. doi: 10.1016/j.vaccine.2016.02.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
82.Alharbi N.K., Padron-Regalado E., Thompson C.P., Kupke A., Wells D., Sloan M.A., Grehan K., Temperton N., Lambe T., Warimwe G., et al. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. Vaccine. 2017;35:3780–3788. doi: 10.1016/j.vaccine.2017.05.032. [DOI] [PMC free article] [PubMed] [Google Scholar]
83.van Doremalen N., Haddock E., Feldmann F., Meade-White K., Bushmaker T., Fischer R.J., Okumura A., Hanley P.W., Saturday G., Edwards N.J., et al. A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques. Sci. Adv. 2020;6:eaba8399. doi: 10.1126/sciadv.aba8399. [DOI] [PMC free article] [PubMed] [Google Scholar]
84.Rauch S., Jasny E., Schmidt K.E., Petsch B. New Vaccine Technologies to Combat Outbreak Situations. Front. Immunol. 2018;9:1963. doi: 10.3389/fimmu.2018.01963. [DOI] [PMC free article] [PubMed] [Google Scholar]
85.Sahin U., Karikó K., Türeci Ö. mRNA-based therapeutics—Developing a new class of drugs. Nat. Rev. Drug Discov. 2014;13:759–780. doi: 10.1038/nrd4278. [DOI] [PubMed] [Google Scholar]
86.Ahmed S.F., Quadeer A.A., McKay M.R. Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies. Viruses. 2020;12:254. doi: 10.3390/v12030254. [DOI] [PMC free article] [PubMed] [Google Scholar]
87.Phan T. Genetic diversity and evolution of SARS-CoV-2. Infect. Genet. Evol. 2020;81:104260. doi: 10.1016/j.meegid.2020.104260. [DOI] [PMC free article] [PubMed] [Google Scholar]
88.Ugurel O.M., Ata O., Turgut-Balik D. An updated analysis of variations in SARS-CoV-2 genome. Turk. J. Biol.—Turk biyoloji dergisi. 2020;44:157–167. doi: 10.3906/biy-2005-111. [DOI] [PMC free article] [PubMed] [Google Scholar]
89.Lim M., Badruddoza A.Z.M., Firdous J., Azad M., Mannan A., Al-Hilal T.A., Cho C.S., Islam M.A. Engineered Nanodelivery Systems to Improve DNA Vaccine Technologies. Pharmaceutics. 2020;12:30. doi: 10.3390/pharmaceutics12010030. [DOI] [PMC free article] [PubMed] [Google Scholar]
90.Smith T.R.F., Patel A., Ramos S., Elwood D., Zhu X., Yan J., Gary E.N., Walker S.N., Schultheis K., Purwar M., et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat. Commun. 2020;11:2601. doi: 10.1038/s41467-020-16505-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
91.Pandey S.C., Pande V., Sati D., Upreti S., Samant M. Vaccination strategies to combat novel corona virus SARS-CoV-2. Life Sci. 2020;256:117956. doi: 10.1016/j.lfs.2020.117956. [DOI] [PMC free article] [PubMed] [Google Scholar]
92.Spruth M., Kistner O., Savidis-Dacho H., Hitter E., Crowe B., Gerencer M., Brühl P., Grillberger L., Reiter M., Tauer C., et al. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses. Vaccine. 2006;24:652–661. doi: 10.1016/j.vaccine.2005.08.055. [DOI] [PMC free article] [PubMed] [Google Scholar]
93.Thèves C., Crubézy E., Biagini P. History of Smallpox and Its Spread in Human Populations. Microbiol. Spectr. 2016;4:161–172. doi: 10.1128/microbiolspec.PoH-0004-2014. [DOI] [PubMed] [Google Scholar]
94.Foley K.E. A Brief Overview of All the Covid-19 Vaccines in the Pipeline. [(accessed on 29 June 2020)]; Available online: https://qz.com/1854077/a-brief-overview-of-all-the-covid-19-vaccines-in-the-pipeline/
95.Gupta T., Gupta S.K. Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses. Int. Immunopharmacol. 2020;86:106717. doi: 10.1016/j.intimp.2020.106717. [DOI] [PMC free article] [PubMed] [Google Scholar]
96.Garçon N., Vaughn D.W., Didierlaurent A.M. Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion. Expert Rev. Vaccines. 2012;11:349–366. doi: 10.1586/erv.11.192. [DOI] [PubMed] [Google Scholar]

[B1-vaccines-08-00474] 1.Hamed M.A. An overview on COVID-19: Reality and expectation. Bull. Natl. Res. Cent. 2020;44:86. doi: 10.1186/s42269-020-00341-9. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B2-vaccines-08-00474] 2.Worldometer COVID-19 Pandemic Data Update. [(accessed on 27 July 2020)];2020 Available online: https://www.worldometers.info/coronavirus/

[B3-vaccines-08-00474] 3.Zhu F.C., Guan X.H., Li Y.H., Huang J.Y., Jiang T., Hou L.H., Li J.X., Yang B.F., Wang L., Wang W.J., et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020 doi: 10.1016/S0140-6736(20)31605-6. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B4-vaccines-08-00474] 4.Zhang T., He Y., Xu W., Ma A., Yang Y., Xu K.F. Clinical trials for the treatment of Coronavirus disease 2019 (COVID-19): A rapid response to urgent need. Sci. China Life Sci. 2020;63:774–776. doi: 10.1007/s11427-020-1660-2. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B5-vaccines-08-00474] 5.Md Insiat Islam R. Current Drugs with Potential for Treatment of COVID-19: A Literature Review. J. Pharm. Pharm. Sci. 2020;23:58–64. doi: 10.18433/jpps31002. [DOI] [PubMed] [Google Scholar]

[B6-vaccines-08-00474] 6.Savioli F. Is there a rationale for heparin use among severe COVID-19 patients? Einstein. 2020;18:eED5758. doi: 10.31744/einstein_journal/2020ED5758. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B7-vaccines-08-00474] 7.Osama El-Gendy A., Saeed H., Ali A.M.A., Zawbaa H.M., Gomaa D., Harb H.S., Madney Y.M., Osama H., Abdelrahman M.A., Abdelrahim M.E.A. Bacillus Calmette–Guérin vaccine, antimalarial, age and gender relation to COVID-19 spread and mortality. Vaccine. 2020;38:5564–5568. doi: 10.1016/j.vaccine.2020.06.083. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B8-vaccines-08-00474] 8.ChiCTR2000031809 A Randomized, Double-Blind, Placebo Parallel-Controlled Phase I/II Clinical Trial for Inactivated Novel Coronavirus Pneumonia Vaccine (Vero Cells) [(accessed on 27 July 2020)];2020 Available online: http://www.chictr.org.cn/hvshowproject.aspx?id=27698.

[B9-vaccines-08-00474] 9.ChiCTR2000032459 A Phase I/II Clinical Trial for Inactivated Novel Coronavirus (2019-CoV) Vaccine (Vero Cells) [(accessed on 27 July 2020)];2020 Available online: http://www.chictr.org.cn/showprojen.aspx?proj=53003.

[B10-vaccines-08-00474] 10.Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19) [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04383574.

[B11-vaccines-08-00474] 11.Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19) [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04352608.

[B12-vaccines-08-00474] 12.Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04412538.

[B13-vaccines-08-00474] 13.ChiCTR2000034112 A Phase I Clinical Trial to Evaluate the Safety, Tolerance and Preliminary Immunogenicity of Different Doses of a SARS-CoV-2 mRNA Vaccine in Population Aged 18-59 Years and 60 Years and Above. [(accessed on 27 July 2020)];2020 Available online: http://www.chictr.org.cn/hvshowproject.aspx?id=40018.

[B14-vaccines-08-00474] 14.ChiCTR2000034825 A Phase I clinical trial of novel coronavirus pneumonia (COVID-19) mRNA Vaccine (BNT162b1) in China 2020. [(accessed on 27 July 2020)];2020 Available online: http://www.chictr.org.cn/showprojen.aspx?proj=56834.

[B15-vaccines-08-00474] 15.EUCTR 2020-001038-36-DE Study to Investigate the Safety and Effects of Vaccines in Healthy Adults. [(accessed on 27 July 2020)];2020 Available online: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001038-36.

[B16-vaccines-08-00474] 16.A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04449276.

[B17-vaccines-08-00474] 17.Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19) [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04283461.

[B18-vaccines-08-00474] 18.Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04368728.

[B19-vaccines-08-00474] 19.A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04380701.

[B20-vaccines-08-00474] 20.Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04405076.

[B21-vaccines-08-00474] 21.ISRCTN17072692 Clinical Trial to Assess the Safety of a Coronavirus Vaccine in Healthy Men and Women. [(accessed on 27 July 2020)];2020 Available online: http://www.isrctn.com/ISRCTN17072692.

[B22-vaccines-08-00474] 22.CTRI/2020/07/026352 Novel Corona Virus-2019-nCov Vaccine by Intradermal Route in Healthy Subjects. [(accessed on 27 July 2020)];2020 Available online: http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45306.

[B23-vaccines-08-00474] 23.Study of COVID-19 DNA Vaccine (AG0301-COVID19) [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04463472.

[B24-vaccines-08-00474] 24.Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04447781.

[B25-vaccines-08-00474] 25.Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04445389.

[B26-vaccines-08-00474] 26.Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04334980.

[B27-vaccines-08-00474] 27.Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04336410.

[B28-vaccines-08-00474] 28.ChiCTR2000030906 A Phase I Clinical Trial for Recombinant Novel Coronavirus (2019-COV) Vaccine (Adenoviral Vector) [(accessed on 27 July 2020)];2020 Available online: http://www.chictr.org.cn/hvshowproject.aspx?id=24074.

[B29-vaccines-08-00474] 29.ChiCTR2000031781 A Randomized, Double-Blinded, Placebo-Controlled Phase II Clinical Trial for Recombinant Novel Coronavirus (2019-nCOV) Vaccine (Adenovirus Vector) [(accessed on 27 July 2020)];2020 Available online: http://www.chictr.org.cn/showprojen.aspx?proj=52006.

[B30-vaccines-08-00474] 30.Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04398147.

[B31-vaccines-08-00474] 31.Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04313127.

[B32-vaccines-08-00474] 32.A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector) [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04341389.

[B33-vaccines-08-00474] 33.COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04444674.

[B34-vaccines-08-00474] 34.A Study of a Candidate COVID-19 Vaccine (COV001) [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04324606.

[B35-vaccines-08-00474] 35.Development An Open Study of the Safety, Tolerability and Immunogenicity of the Drug “Gam-COVID-Vac” Vaccine Against COVID-19. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04436471.

[B36-vaccines-08-00474] 36.Development An Open Study of the Safety, Tolerability and Immunogenicity of “Gam-COVID-Vac Lyo” Vaccine Against COVID-19. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04437875.

[B37-vaccines-08-00474] 37.ACTRN12620000674932 An Interventional Study to Evaluate the Safety and Immune Response of a Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2, the Virus that Causes COVID-19 Infection) when Given to Healthy Adult Participants. [(accessed on 27 July 2020)];2020 Available online: http://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000674932.

[B38-vaccines-08-00474] 38.Monovalent Recombinant COVID19 Vaccine. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04453852.

[B39-vaccines-08-00474] 39.Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04445194.

[B40-vaccines-08-00474] 40.KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04473690.

[B41-vaccines-08-00474] 41.Clinical Study of Recombinant Novel Coronavirus Vaccine. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04466085.

[B42-vaccines-08-00474] 42.Novavax Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04368988.

[B43-vaccines-08-00474] 43.SCB-2019 as COVID-19 Vaccine. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04405908.

[B44-vaccines-08-00474] 44.Therapeutic Vaccine Trial of COVID-19 for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04428073.

[B45-vaccines-08-00474] 45.Immunity and Safety of Covid-19 Synthetic Minigene Vaccine. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04276896.

[B46-vaccines-08-00474] 46.Phase Ib-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04386252.

[B47-vaccines-08-00474] 47.ChiCTR2000030750 A Clinical Study for Effectiveness and Safety Evaluation for Recombinant Chimeric COVID-19 Epitope DC Vaccine in the Treatment of Novel Coronavirus Pneumonia. [(accessed on 27 July 2020)];2020 Available online: http://www.chictr.org.cn/showproj.aspx?proj=50928.

[B48-vaccines-08-00474] 48.Safety and Immunity of Covid-19 aAPC Vaccine. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04299724.

[B49-vaccines-08-00474] 49.Medicago Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04450004.

[B50-vaccines-08-00474] 50.ISRCTN89951424 A Phase III Study to Investigate a Vaccine Against COVID-19. [(accessed on 27 July 2020)];2020 Available online: http://www.isrctn.com/ISRCTN90853814:2020.

[B51-vaccines-08-00474] 51.Investigating a Vaccine Against COVID-19. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04400838.

[B52-vaccines-08-00474] 52.EUCTR2020-001228-32-GB Investigating a Vaccine Against COVID-19. [(accessed on 27 July 2020)];2020 Available online: https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001228-32/GB.

[B53-vaccines-08-00474] 53.ChiCTR2000034780 A Phase III Clinical Trial for Inactivated Novel Coronavirus Pneumonia (COVID-19) Vaccine (Vero Cells) [(accessed on 27 July 2020)];2020 Available online: http://www.chictr.org.cn/hvshowproject.aspx?id=43780.

[B54-vaccines-08-00474] 54.Clinical Trial of Efficacy and Safety of Sinovac’s Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04456595.

[B55-vaccines-08-00474] 55.A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04470427.

[B56-vaccines-08-00474] 56.Nasrollahzadeh M., Sajjadi M., Soufi G.J., Iravani S., Varma R.S. Nanomaterials and Nanotechnology-Associated Innovations against Viral Infections with a Focus on Coronaviruses. Nanomaterials. 2020;10:1072. doi: 10.3390/nano10061072. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B57-vaccines-08-00474] 57.Itani R., Tobaiqy M., Al Faraj A. Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients. Theranostics. 2020;10:5932–5942. doi: 10.7150/thno.46691. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B58-vaccines-08-00474] 58.Wang F., Kream R.M., Stefano G.B. An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development. Med. Sci. Monit. 2020;26:e924700. doi: 10.12659/MSM.924700. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B59-vaccines-08-00474] 59.Wadman M. Antivaccine forces gaining online. Science. 2020;368:699. doi: 10.1126/science.368.6492.699. [DOI] [PubMed] [Google Scholar]

[B60-vaccines-08-00474] 60.Pagliusi S., Jarrett S., Hayman B., Kreysa U., Prasad S.D., Reers M., Hong Thai P., Wu K., Zhang Y.T., Baek Y.O., et al. Emerging manufacturers engagements in the COVID −19 vaccine research, development and supply. Vaccine. 2020;38:5418–5423. doi: 10.1016/j.vaccine.2020.06.022. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B61-vaccines-08-00474] 61.Hodgson J. The pandemic pipeline. Nat. Biotechnol. 2020;38:523–532. doi: 10.1038/d41587-020-00005-z. [DOI] [PubMed] [Google Scholar]

[B62-vaccines-08-00474] 62.Amanat F., Krammer F. SARS-CoV-2 Vaccines: Status Report. Immunity. 2020;52:583–589. doi: 10.1016/j.immuni.2020.03.007. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B63-vaccines-08-00474] 63.Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04332835.

[B64-vaccines-08-00474] 64.Selçuk A.A. A Guide for Systematic Reviews: PRISMA. Turk. Arch. Otorhinolaryngol. 2019;57:57–58. doi: 10.5152/tao.2019.4058. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B65-vaccines-08-00474] 65.WHO DRAFT Landscape of COVID-19 Candidate Vaccines. [(accessed on 30 June 2020)]; Available online: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.

[B66-vaccines-08-00474] 66.Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04471519.

[B67-vaccines-08-00474] 67.Prevention Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged ⩾60 Years. [(accessed on 27 July 2020)];2020 Available online: https://ClinicalTrials.gov/show/NCT04470609.

[B68-vaccines-08-00474] 68.Rees V. Germany to Begin First Clinical Trial of COVID-19 Vaccine Candidate. [(accessed on 30 June 2020)]; Available online: https://www.europeanpharmaceuticalreview.com/news/117624/germany-to-begin-first-clinical-trial-of-covid-19-vaccine-candidate/

[B69-vaccines-08-00474] 69.Gao Q., Bao L., Mao H., Wang L., Xu K., Yang M., Li Y., Zhu L., Wang N., Lv Z., et al. Rapid development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020 doi: 10.1126/science.abc1932. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B70-vaccines-08-00474] 70.Chen X., Han W., Wang G., Zhao X. Application prospect of polysaccharides in the development of anti-novel coronavirus drugs and vaccines. Int. J. Biol. Macromol. 2020;164:331–343. doi: 10.1016/j.ijbiomac.2020.07.106. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B71-vaccines-08-00474] 71.Jean S.S., Lee P.I., Hsueh P.R. Treatment options for COVID-19: The reality and challenges. J. Microbiol. Immunol. Infect.—Wei mian yu gan ran za zhi. 2020;53:436–443. doi: 10.1016/j.jmii.2020.03.034. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B72-vaccines-08-00474] 72.Shadmi E., Chen Y., Dourado I., Faran-Perach I., Furler J., Hangoma P., Hanvoravongchai P., Obando C., Petrosyan V., Rao K.D., et al. Health equity and COVID-19: Global perspectives. Int. J. Equity Health. 2020;19:104. doi: 10.1186/s12939-020-01218-z. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B73-vaccines-08-00474] 73.Thanh Le T., Andreadakis Z., Kumar A., Gómez Román R., Tollefsen S., Saville M., Mayhew S. The COVID-19 vaccine development landscape. Nat. Rev. Drug Discov. 2020;19:305–306. doi: 10.1038/d41573-020-00073-5. [DOI] [PubMed] [Google Scholar]

[B74-vaccines-08-00474] 74.Tan W.G., Jin H.T., West E.E., Penaloza-MacMaster P., Wieland A., Zilliox M.J., McElrath M.J., Barouch D.H., Ahmed R. Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors. J. Virol. 2013;87:1359–1372. doi: 10.1128/JVI.02055-12. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B75-vaccines-08-00474] 75.Folegatti P.M., Ewer K.J., Aley P.K., Angus B., Becker S., Belij-Rammerstorfer S., Bellamy D., Bibi S., Bittaye M., Clutterbuck E.A., et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020 doi: 10.1016/S0140-6736(20)31604-4. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B76-vaccines-08-00474] 76.Afrough B., Dowall S., Hewson R. Emerging viruses and current strategies for vaccine intervention. Clin. Exp. Immunol. 2019;196:157–166. doi: 10.1111/cei.13295. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B77-vaccines-08-00474] 77.Cohen J. Vaccine designers take first shots at COVID-19. Science. 2020;368:14–16. doi: 10.1126/science.368.6486.14. [DOI] [PubMed] [Google Scholar]

[B78-vaccines-08-00474] 78.Ura T., Okuda K., Shimada M. Developments in Viral Vector-Based Vaccines. Vaccines. 2014;2:624–641. doi: 10.3390/vaccines2030624. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B79-vaccines-08-00474] 79.Ewer K.J., Lambe T., Rollier C.S., Spencer A.J., Hill A.V., Dorrell L. Viral vectors as vaccine platforms: From immunogenicity to impact. Curr. Opin. Immunol. 2016;41:47–54. doi: 10.1016/j.coi.2016.05.014. [DOI] [PubMed] [Google Scholar]

[B80-vaccines-08-00474] 80.Zhu F.C., Li Y.H., Guan X.H., Hou L.H., Wang W.J., Li J.X., Wu S.P., Wang B.S., Wang Z., Wang L., et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395:1845–1854. doi: 10.1016/S0140-6736(20)31208-3. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B81-vaccines-08-00474] 81.Klug B., Robertson J.S., Condit R.C., Seligman S.J., Laderoute M.P., Sheets R., Williamson A.L., Gurwith M., Kochhar S., Chapman L., et al. Adventitious agents and live viral vectored vaccines: Considerations for archiving samples of biological materials for retrospective analysis. Vaccine. 2016;34:6617–6625. doi: 10.1016/j.vaccine.2016.02.015. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B82-vaccines-08-00474] 82.Alharbi N.K., Padron-Regalado E., Thompson C.P., Kupke A., Wells D., Sloan M.A., Grehan K., Temperton N., Lambe T., Warimwe G., et al. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. Vaccine. 2017;35:3780–3788. doi: 10.1016/j.vaccine.2017.05.032. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B83-vaccines-08-00474] 83.van Doremalen N., Haddock E., Feldmann F., Meade-White K., Bushmaker T., Fischer R.J., Okumura A., Hanley P.W., Saturday G., Edwards N.J., et al. A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques. Sci. Adv. 2020;6:eaba8399. doi: 10.1126/sciadv.aba8399. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B84-vaccines-08-00474] 84.Rauch S., Jasny E., Schmidt K.E., Petsch B. New Vaccine Technologies to Combat Outbreak Situations. Front. Immunol. 2018;9:1963. doi: 10.3389/fimmu.2018.01963. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B85-vaccines-08-00474] 85.Sahin U., Karikó K., Türeci Ö. mRNA-based therapeutics—Developing a new class of drugs. Nat. Rev. Drug Discov. 2014;13:759–780. doi: 10.1038/nrd4278. [DOI] [PubMed] [Google Scholar]

[B86-vaccines-08-00474] 86.Ahmed S.F., Quadeer A.A., McKay M.R. Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies. Viruses. 2020;12:254. doi: 10.3390/v12030254. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B87-vaccines-08-00474] 87.Phan T. Genetic diversity and evolution of SARS-CoV-2. Infect. Genet. Evol. 2020;81:104260. doi: 10.1016/j.meegid.2020.104260. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B88-vaccines-08-00474] 88.Ugurel O.M., Ata O., Turgut-Balik D. An updated analysis of variations in SARS-CoV-2 genome. Turk. J. Biol.—Turk biyoloji dergisi. 2020;44:157–167. doi: 10.3906/biy-2005-111. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B89-vaccines-08-00474] 89.Lim M., Badruddoza A.Z.M., Firdous J., Azad M., Mannan A., Al-Hilal T.A., Cho C.S., Islam M.A. Engineered Nanodelivery Systems to Improve DNA Vaccine Technologies. Pharmaceutics. 2020;12:30. doi: 10.3390/pharmaceutics12010030. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B90-vaccines-08-00474] 90.Smith T.R.F., Patel A., Ramos S., Elwood D., Zhu X., Yan J., Gary E.N., Walker S.N., Schultheis K., Purwar M., et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat. Commun. 2020;11:2601. doi: 10.1038/s41467-020-16505-0. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B91-vaccines-08-00474] 91.Pandey S.C., Pande V., Sati D., Upreti S., Samant M. Vaccination strategies to combat novel corona virus SARS-CoV-2. Life Sci. 2020;256:117956. doi: 10.1016/j.lfs.2020.117956. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B92-vaccines-08-00474] 92.Spruth M., Kistner O., Savidis-Dacho H., Hitter E., Crowe B., Gerencer M., Brühl P., Grillberger L., Reiter M., Tauer C., et al. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses. Vaccine. 2006;24:652–661. doi: 10.1016/j.vaccine.2005.08.055. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B93-vaccines-08-00474] 93.Thèves C., Crubézy E., Biagini P. History of Smallpox and Its Spread in Human Populations. Microbiol. Spectr. 2016;4:161–172. doi: 10.1128/microbiolspec.PoH-0004-2014. [DOI] [PubMed] [Google Scholar]

[B94-vaccines-08-00474] 94.Foley K.E. A Brief Overview of All the Covid-19 Vaccines in the Pipeline. [(accessed on 29 June 2020)]; Available online: https://qz.com/1854077/a-brief-overview-of-all-the-covid-19-vaccines-in-the-pipeline/

[B95-vaccines-08-00474] 95.Gupta T., Gupta S.K. Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses. Int. Immunopharmacol. 2020;86:106717. doi: 10.1016/j.intimp.2020.106717. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B96-vaccines-08-00474] 96.Garçon N., Vaughn D.W., Didierlaurent A.M. Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion. Expert Rev. Vaccines. 2012;11:349–366. doi: 10.1586/erv.11.192. [DOI] [PubMed] [Google Scholar]

PERMALINK

Current Clinical Trials Protocols and the Global Effort for Immunization against SARS-CoV-2

Gabriel N A Rego

Mariana P Nucci

Arielly H Alves

Fernando A Oliveira

Luciana C Marti

Leopoldo P Nucci

Javier B Mamani

Lionel F Gamarra

Abstract

1. Introduction

2. Methods

2.1. Search Strategy

2.2. Inclusion and Exclusion Criteria

2.3. Data Extraction, Data Collection, and Risk of Bias Assessment

2.4. Data Analysis

3. Results

3.1. Study Selection

3.2. Overview of Clinical Trial Protocols for Active Immunization for Covid-19

Table 1.

Figure 1.

3.3. Properties and Features of Vaccines against COVID-19

3.3.1. Nucleic Acid Vaccines

Figure 2.

RNA Vaccines

DNA Vaccines

Table 2.

3.3.2. Non-Replicating Viral Vector Vaccines

3.3.3. Inactivated Virus Vaccines

3.3.4. Protein Subunit Vaccines

3.3.5. Dendritic Cells Vaccines

3.3.6. Virus Like Particles Vaccines

3.4. Trial Progression Rate

Figure 3.

3.5. Study Design of Clinical Trial Protocols

Figure 4.

3.6. Global Research Network in Clinical Trial Protocols

Figure 5.

Figure 6.

4. Discussion

5. Conclusions

Appendix A

Table A1.

Author Contributions

Funding

Conflicts of Interest

References

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases